7
13
c.33
78

THE
FRAMINGHAM
STUDY

An Epidemiological Investigation
of
Cardiovascular Disease

Section 33

Index to Previous Sections 1-32

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service National Institutes of Health

Library
National Institutes of Health
Bethesda, Maryland 20014

Free approved 7-25-79 xp

THE
FRAMINGHAM
STUDY

An Epidemiological Investigation of Cardiovascular Disease

Editors: William B. Kannel, M.D., and Tavia Gordon

Section 33. An Index to Previous Sections 1-32

Constantine Gillespie and Paul Sorlie

December, 1978

National Heart, Lung, and Blood Institute

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service National Institutes of Health

NIH PUBLICATION NO. 79-1671

For sale by the Superintendent of Documents, U.S. Government Printing Office
Washington, D.C. 20402
Stock Number 017-040-00452-4

RC
667
F813
sec. 33
1978

PREFACE

The National Heart, Lung, and Blood Institute has published 32 volumes in a monograph series on the Framingham Heart Study between 1968 and 1977. This index contains subject references to the text, tables and figures contained in the 32 volumes. There are guides (guide 1 through guide 7) at the end of the index which contain detailed cross-referencing of tabulations by personal attributes and by disease end points. References to these guides are made throughout the main section of this index.

Reference is made by monograph section number and by page, table or figure number in the following manner:

32:15	means section 32, page 15
25:table 1A	means section 25, table 1A
23:figure 4	means section 23, figure 4
see guide 2	means look up guide number 2 found in the back of this index.

Mr. Constantine Gillespie was formerly chief of the Reference and Bibliographic Services Section of the National Institutes of Health Library. Mr. Paul Sorlie is a statistician in the Biometrics Research Branch of the National Heart, Lung, and Blood Institute.

ACCIDENTS
  as cause of death, 1:table 1-8

ADIPOSITY: see BODY WEIGHT

AGE GROUPS: see guides 1 through 7

AGE TRENDS
  in abnormal ECG findings, 29:42
  in blood glucose, 29:34, 29:figure 4
  in body weight, 29:35-36
  in cigarette smoking, 29:40-41
  in cigarettes smoked, 29:38-39
  in diabetes mellitus, 29:43
  in diastolic blood pressure, 29:32-34, 29:figure 2
  in heart enlargement by x-ray, 29:42-43, 29:figure 11
  in hematocrit, 29:35, 29:figure 5
  in hypertension, 29:43
  in intraventricular conduction defects, 29:42, 29:figure 10
  in left ventricular hypertrophy by ECG, 29:42, 29:figure 9
  in pulse rate, 29:35, 29:figure 7
  in relative body weight, 29:36-38
  in serum cholesterol, 29:34, figure 3
  in systolic blood pressure, 29:27-32, 29:figure 1
  in systolic blood pressure according to treatment status for exams 3-10, 29:figure 1b
  in urine albumin, 29:41
  in urine glucose, 29:41, 29:figure 8
  in vital capacity, 29:35, figure 6

ALBANY CARDIOVASCULAR HEALTH CENTER STUDY: see POOLING PROJECT

ALBUMINURIA: see URINE ALBUMIN

ALCOHOL CONSUMPTION PER MONTH
  correlations with other characteristics, see guide 2
  distribution of levels at exams 1-7, 9:table 9-A-1, 9:table 9-B-1
  incidence of disease according to, see guide 3, guide 5
  mean values at exams 1-7, 4:table 4-1, see also guide 1
  mean values by response characteristics, see guide 1
  standard errors at exams 1-7, 3:table 3-1

ANGINA PECTORIS (AP)
  cardiovascular diseases and death after, 20-year followup, 32:1-103
  characteristics associated with prognosis, 32:table VI-1 through table VI-4, 32:table VI-10 through table VI-13
  criteria for,
    in 14-year followup, 8:8-criteria-2
    in 16-year followup, 26:17-18
    in 18-year followup, 28:8, 30:17-18, 20
    in life tables, 25:17, 32:5-6, 9
  discriminant analysis, 23:table 23-E, 23:figure 23-6, 23:figure 23-7, 23:figure 23-8, 23:figure 23-9, 23:figure 23-10, 23:figure 23-11, see also guide 4
  fitted probability of development, 27:figure 3, 27:figure 4
  following recognized myocardial infarction, 32:table II-9, 32:table III-9
  incidence in 14-year followup, 6:table 6-6, 6:table 6-7 7:table 7-6, 7:table 7-7, 8:table 8A-6, 8:table 8A-7, 8:table 8B-6, 8:table 8B-7, 8:table 8C-6, 8:table 8C-7, see also guide 3
  incidence in 16-year followup, see guide 5, guide 6

ANGINA PECTORIS (AP), Continued
  incidence in 18-year followup, see guide 7
  life tables for diseases following angina pectoris:
    cardiovascular death, 32:table II-3, 32:table III-3, 32:figure V-3
    cerebrovascular accident, 32:table II-7, 32:table III-7, 32:figure V-7
    congestive heart failure, 32:table II-6, 32:table III-6, 32:figure V-6
    coronary attack, 32:table II-4, 32:table III-4, 32:figure V-4
    death, 25:table 3A, 25:figure 3A, 32:table II-1, 32:table III-1, 32:figure V-1
    myocardial infarction, 32:table II-5, 32:table III-5, 32:figure V-5
    sudden death, 32:table II-2, 32:table III-2, 32:figure V-2
  life tables for, in total Framingham study population, 32:table IV-6
  regression coefficient by 19 characteristics for men and women at 16-year followup, 27:table 15, 27:table 16
  vs. myocardial infarction, discriminant statistics, 23:table 23-B

ARTERIOSCLEROSIS
  Framingham study of, rationale, 1:1b-1-6

ATHEROTHROMBOTIC BRAIN INFARCTION (ABI)
- criteria for,
  - in 14-year followup, 8:8-criteria-4
  - in 16-year followup, 26:21
  - in 18-year followup, 28:10, 30:22-23
- discriminant analysis 23:table 23-I, 23:figure 23-12, 23:figure 23-13, 23:figure 23-14, 23:figure 23-15, 23:figure 23-16, 23:figure 23-17, see also guide 4
- fitted probability of development, 16-year followup, 27:figure 1, 27:figure 2
- incidence in 14-year followup, 6:table 6-10, 7:table 7-10, 8:table 8A-10, 8:table 8C-10, see guide 3, guide 4
- incidence in 16-year followup, see guide 5, guide 6
- incidence in 18-year followup, see guide 7
- life tables for death following ABI, 25:table 7A, 25:table 7B, 25:figure 7A
- probability of development in 8 years, according to risk factors, 28:table 3
- regression coefficient by 19 characteristics for men and women at 16-year followup, 27:table 15, 27:table 16
- risk deciles, 16-year followup, 27:table 18, 27:figure 5

ATRIAL FIBRILLATION
- designated by ECG, 29:15

ATRIAL FLUTTER
- designated by ECG, 29:15-16

BLOOD GLUCOSE
- age trends in, 29:34, 29:figure 4
- correlation between 2 exams for all subjects and for subjects taking exam 10, by sex, 29:table C-4

BLOOD GLUCOSE, Continued
- correlation with other characteristics, see guide 2
- determination of, 29:8-9, 30:28
- distribution of levels at exams 1-7, 9:table 9-A-4, 9:table 9-B-4
- incidence of disease according to, see guide 3, guide 5, guide 6, guide 7
- mean value at exam 1 for all subjects, for subjects taking exam 10, and for subjects not taking exam 10, 29:table 4
- mean values at exams 1-7, 4:table 4-8, see also guide 1
- mean values at exams 1-10, 29:table A-4
- mean values for subjects taking exam 10, 29:table B-4
- standard errors at exams 1-7, 3:table 3-8
- variation, intraindividual, 29:table 4 appendix 2

BLOOD PRESSURE, DIASTOLIC (DBP), see also HYPERTENSION
- age trends, 29:32-34, 29:figure 2
- correlation between 2 exams, 29:table C-2
- correlation with other characteristics, see guide 2
- determination of, 29:7-8, 30:26-27
- distribution of levels at exams 1-7, 9:table 9-A-3, 9:table 9-B-3
- distribution of levels by studies in pooling project, 31:table 9, 31:figure 2
- incidence of disease according to, see guide 3, guide 5, guide 7
- mean level by time of determinations, exams 1-7, 23:figure 23-4
- mean value at exam 1 by response to exam 10, 29:table 2
  - excluding subjects on hypotensives, 29:table 2A
- mean values at exams 1-7, see also guide 1
  - admission reading, 4:table 4-3
  - first examiner reading, 4:table 4-5
  - second examiner reading, 4:table 4-7

BLOOD PRESSURE, DIASTOLIC (DBP), Continued
  mean values at exams 1-10, 29:table A-2
    for subjects taking exam 10, 29:table B-2
    for subjects not on hypotensives, 29:table B-2A
    for subjects on hypotensives, 29:table B-2B
  risk factor in studies of pooling project, mean values and standard deviations of, 31:table 5
  standard errors at exams 1-7, 3:table 3-3, 3-5, 3-7
  variation, intraindividual, 29:table 2 appendix 2

BLOOD PRESSURE, SYSTOLIC (SBP), see also HYPERTENSION
  age trends for exams 3-10, 29:27, 29:figure 1a
    by treatment status, 29:figure 1b
    cross sectional and cohort trends, 29:figure 1
  as discriminator of cardiovascular disease, 23:1-54
  correlation between 2 exams, 29:table C-1
  correlation with other characteristics, see guide 2
  determination of, 28:13-14, 29:7-8, 30:26-27
  discriminant analysis with respect to:
    see also guide 4
    brain infarction, 23:table 23-I
    cerebrovascular accident, 23:table 23-H
    congestive heart failure, 23:table 23-K
    coronary heart disease, 23:table 23-A
    death from all causes, 23:table 23-L
    death from coronary heart disease, 23:table 23-M
    death from noncardiovascular causes, 23:table 23-O
    intermittent claudication, 23:table 23-J
    myocardial infarction, 23:table 23-D
    nonsudden death from coronary heart disease, 23:table 23-G
    other cardiovascular deaths, 23:table 23-N
    sudden death from coronary heart disease, 23:table 23-F
    uncomplicated angina pectoris, 23:table 23-E

BLOOD PRESSURE, SYSTOLIC (SBP), Continued
  discriminant statistics in fatal vs. nonfatal coronary heart disease in men at 14-year followup, 23:table 23-C
  discriminant statistics in myocardial infarction vs. angina pectoris in men at 14-year followup, 23:table 23-B
  distribution of levels at exams 1-7, 9:table 9-A-2, 9:table 9-B-2
  distribution of levels by studies in pooling project, 31:table 8, 31:figure 1
  incidence of disease according to, see guide 3 through guide 7
  mean level by age in men developing and not developing coronary heart disease, 23:figure 23-5
  mean level by time of determinations, exams 1-7, 23:figure 23-3
  mean value at exam 1 by response to exam 10, 29:table 1
    excluding subjects on hypotensives, 29:table 1A
  mean values at exams 1-7, see also guide 1
    admission reading, 4:table 4-2
    first examiner reading, 4:table 4-4
    second examiner reading, 4:table 4-6
  mean values at exams 1-10, 29:table A-1
    for subjects taking exam 10, 29:table B-1
    for subjects not on hypotensives, 29:table B-1A
    for subjects on hypotensives, 29:table B-1B
  mean values by disease status,
    men, 23:figure23-8, 23:figure 23-14, 23:figure 23-20
    women, 23:figure 23-10, 23:figure 23-17, 23:figure 23-23
  nomograms of CHD risk by level of systolic blood pressure,
    40 years of age, 23:figure 23-24, 23:figure 23-30
    45 years of age, 23:figure 23-25, 23:figure 23-31
    50 years of age, 23:figure 23-26, 23:figure 23-32

BLOOD PRESSURE, SYSTOLIC (SBP), Continued
  nomograms of CHD, Continued
      55 years of age, 23:figure 23-27, 23:figure 23-33
      60 years of age, 23:figure 23-28, 23:figure 23-34
      65 years of age, 23:figure 23-29, 23:figure 23-35
  probability of cardiovascular diseases by level of systolic blood pressure,
      16-year followup, 27:tables 1B-4B
      18-year followup, 28:tables 1-5
  regression coefficients for cardiovascular diseases on systolic blood pressure, 27:tables 1-4,
  risk factor in studies of pooling project, mean values and standard deviations of, 31:table 5
  standard errors at exams 1-7, 3:tables 3-2, 3-4, 3-6
  variation, intraindividual, 29:table 1 appendix 2

BLOOD SUGAR: see BLOOD GLUCOSE

BLOOD URIC ACID: see URIC ACID, SERUM

BODY HEIGHT
  vital capacity-height index, determination of, 30:30

BODY WEIGHT, see also FRAMINGHAM RELATIVE WEIGHT;
                      METROPOLITAN RELATIVE WEIGHT;
                      RELATIVE WEIGHT
  age trends in, 29:35-38
  correlation between 2 exams, 29:table C-8
  correlation with other characteristics, see guide 2
  distribution of levels at exams 1-7, 9:table 9-A-13, 9:table 9-B-13
  incidence of disease according to, see guide 3
  mean value at exam 1 for all subjects, for subjects taking exam 10, and for subjects not taking exam 10, 29:table 8

BODY WEIGHT, Continued
  mean value for each 3-month period from January 1957 to September 1960 for men and women in Framingham diet study, 24:figure 5 through figure 6
  mean values at exams 1-7, 4:table 4-17, see also guide 1
  mean values at exams 1-10, 29:table A-8
  mean values for subjects taking exam 10, 29:table B-8
  measurement of, 29:10
  regression of mean weight and weight change on serum cholesterol in Framingham diet study, 24:table 22
  standard errors at exams 1-7, 3:table 3-17
  variation, intraindividual, 29:table 8 appendix 2

BRAIN INFARCTION: see ATHEROTHROMBOTIC BRAIN INFARCTION

CALORIES
  caloric balance in relation to serum cholesterol, 24:6-7
  correlation with serum cholesterol level, 24:table 11
  correlation with physical activity index, 24:11
  correlation with relative weight, 24:10
  daily intake per pound of body weight in Framingham diet study, 24:figure 8
  mean intake by physical activity index and body weight, 24:table 9
  mean value of average daily intake for each 3-month period from January 1957 to September 1960 for men and women in Framingham diet study, 24:figure 1, figure 2
  median intake, 24:figure 7
  percent calories from fat in Framingham diet study, 24:figure 16
  relation to serum cholesterol and physical activity index, 24:table 10

CANCER: see NEOPLASMS

CARBOHYDRATES
- complex/simple carbohydrate ratio, 24:8
- mean serum cholesterol level in relation to, 24:table 16
- mean value by level of serum cholesterol, 24:table 20
- regression on serum cholesterol, 24:table 21

CARDIOVASCULAR DISEASE DEATH
- criteria for,
  - in 14-year followup, 8:8-criteria-6
  - in 16-year followup, 26:23
  - in 18-year followup, 30:25
  - in life tables, 32:9
- discriminant analysis, 23:table 23-N, see also guide 4
- end point event after uncomplicated angina pectoris or myocardial infarction, 32:table 1
- following uncomplicated angina pectoris, 32:table II-3, 32:table III-3, 32:figure V-3
- in drawn sample according to response and sex for years 1951-1952, 1:table 1-8, see also guide 3, guide 4
- incidence in 14-year followup, 1:table 1-9, 6:table 6-18, 8:table 8-A-18, 8:table 8-C-18, see also guide 3, guide 4
- incidence in 16-year followup, see guide 5
- incidence in 18-year followup, see guide 7
- life tables in total Framingham study, 32:table IV-3
- regression coefficient by 19 characteristics for men and women at 16-year followup, 27:table 15, 27:table 16

CARDIOVASCULAR DISEASES
  see also CEREBROVASCULAR ACCIDENT;
    CORONARY HEART DISEASE;
    HEART DISEASES;
    INTERMITTENT CLAUDICATION
  criteria for, 28:11-13, 30:25
  discriminators of, 23:1-54, see also guide 4
  following myocardial infarction and angina pectoris, 20-year followup, 32:1-103
    life table methodology, 32:15-24
    methodology for analyzing factors associated with survival, 32:25-31
  incidence in 18-year followup, see guide 7
  life tables for, in total Framingham study population, 32:table IV-10
  natural history of, 1:1b-2 - 1b-3
  pooling project cooperative epidemiological study of, 31:1-15
  population at risk at exams 2 and 6, 28:appendix 1
  probability of development by specified values of some characteristics, 28:1-21, 28:table 5, 28:appendix B
  survival following certain cardiovascular events, 25:1-5

CEREBROVASCULAR ACCIDENT (CVA)
  see also ATHEROTHROMBOTIC BRAIN INFARCTION
  criteria for,
    in 14-year followup, 8:8-criteria-3
    in 16-year followup, 26:20
    in 18-year followup, 30:21
    in life tables, 32:10
  death due to, in 14-year followup, 6:table 6-17, 8:table 8-A-17, 8:table 8-C-17
  definition as end point event following coronary heart disease, 32:10-11

CEREBROVASCULAR ACCIDENT (CVA), Continued
- diagnosis of, 25:27
- discriminant analysis, 23:table 23-H, 23:figure 23-12, 23:figure 23-13, 23:figure 23-14, see also guide 4
- following recognized myocardial infarction, 32:table II-12
- following uncomplicated angina pectoris, 32:table II-7, 32:table III-7, 32:figure V-7
- following unrecognized myocardial infarction, 32:table II-16
- incidence in 14-year followup, 6:table 6-9, 7:table 7-9, 7:table 7-17, 8:table 8-A-9, 8:table 8-C-9, see also guide 3, guide 4
- incidence in 16-year followup, see guide 5, guide 6
- incidence in 18-year followup, see guide 7
- life tables for, in total Framingham study population, 32:table IV-9
- life tables for mortality following cerebrovascular disease, 25:table 6A, 25:table 6B, 25:figure 6A, 25:figure 6B
- other than brain infarction, incidence at 14-year followup, 6:table 6-11, 7:table 7-11, 8:table 8-A-11, 8:table 8-C-11
- population at risk by sex, at 14-year followup, 8:table 8-B-9 through table 8-B-11
- prevalence at exams 1-7 by level of following characteristics:
  - abnormal ECG, 9:table 9-A-14, 9:table 9-B-14
  - alcohol consumption per month, 9:table 9-A-1, 9:table 9-B-1
  - blood sugar, 9:table 9-A-4, 9:table 9-B-4
  - blood uric acid, 9:table 9-A-11, 9:table 9-B-11
  - body weight, 9:table 9-A-13, 9:table 9-B-13
  - cigarettes smoked, 9:table 9-A-6, 9:table 9-B-6

CEREBROVASCULAR ACCIDENT (CVA), Continued
  prevalence, Continued
    diastolic blood pressure by first examiner, 9:table 9-A-3, 9:table 9-B-3
    Framingham relative weight, 9:table 9-A-7, 9:table 9-B-7
    generalized cardiac enlargement by x-ray, 9:table 9-A-20, 9:table 9-B-20
    heart enlargement by x-ray, 9:table 9-A-21, 9:table 9-B-21
    hematocrit, 9:table 9-A-8, 9:table 9-B-8
    hemoglobin, 9:table 9-A-9, 9:table 9-B-9
    left ventricular hypertrophy by ECG, 9:table 9-A-15, 9:table 9-B-15
    left ventricular hypertrophy by x-ray, 9:table 9-A-22, 9:table 9-B-22
    nonspecific T-wave abnormality by ECG, 9:table 9-A-16, 9:table 9-B-16
    serum cholesterol, 9:table 9-A-5, 9:table 9-B-5
    serum phospholipids, 9:table 9-A-10, 9:table 9-B-10
    smoking now, 9:table 9-A-17, 9:table 9-B-17
    systolic blood pressure by first examiner, 9:table 9-A-2, 9:table 9-B-2
    urine albumin, 9:table 9-A-18, 9:table 9-B-18
    urine sugar, 9:table 9-A-19, 9:table 9-B-19
    vital capacity, 9:table 9-A-12, 9:table 9-B-12
  regression coefficient by 19 characteristics for men and women at 16-year followup, 27:table 15, 27:table 16

CHD: see CORONARY HEART DISEASE

CHF: see HEART FAILURE, CONGESTIVE

CHICAGO PEOPLES GAS COMPANY STUDY:
  see POOLING PROJECT

CHICAGO WESTERN ELECTRIC COMPANY STUDY:
   see POOLING PROJECT

CHOLESTEROL, DIETARY, see also SERUM CHOLESTEROL
  daily intake in Framingham diet study, 24:8-9
    24:figure 20
      influence on mean serum cholesterol level,
        24:table 17
      relation to animal fat intake and cholesterol level,
        24:table 18
      relation to daily intake of animal fat and influence
        on regression serum cholesterol, 24:table 19

CHOLESTEROL, SERUM: see SERUM CHOLESTEROL

CIGARETTE SMOKING, see also CIGARETTES SMOKED PER DAY
  age trends in, 29:38-39, 29:40-41
  correlation with other characteristics, see guide 2
  description of, 28:16-17
  distribution of levels at exams 1-7, 9:table 9-A-17,
    9:table 9-B-17
  incidence of disease according to, see guide 3
  mean values at exams 1-7, 4:table 4-21, see also
    guide 1
  percent agreement between 2 exams, 29:table C-12
  percentage who were smokers, exams 1-10, 29:table 12,
    29:table A-12, 29:table B-12
  probability of cardiovascular diseases by smoking,
    16-year followup, 27:table 1B-4B
    18-year followup, 28:table 1 through table 5
  recording of, 3:notes, 29:13

CIGARETTES SMOKED PER DAY, see also CIGARETTE SMOKING
  correlation between 2 exams, 29:table C-11
  correlation with other characteristics, see guide 2
  distribution of levels at exams 1-7, 9:table 9-B-6
  incidence of disease according to, see guide 3, guide 5 through guide 7
  mean value at exam 1 for all subjects, for subjects taking exam 10, and for subjects not taking exam 10, 29:table 11
  mean value at exams 1-7, 4:table 1-10, see also guide 1
  mean value at exams 1-10, 29:table A-11, 29:table B-11, 29:table B-11A
  recording of, 3:notes, 30:31
  regression coefficients for cardiovascular diseases on smoking, 27:table 1 through table 4
  standard errors at exam 1-7, 3:table 3-10
  variation, intraindividual, 29:table 11 appendix 2

COHORT: see SAMPLE GROUP; VOLUNTEERS

COMMUNITY HEALTH SERVICES
  arrangements for Framingham study, 1:1d-1 - 1d-3

CONDUCTION DEFECT, INTRAVENTRICULAR: see INTRAVENTRICULAR CONDUCTION DEFECT

CONGESTIVE HEART FAILURE: see HEART FAILURE, CONGESTIVE

CORONARY ATTACK
  after uncomplicated angina pectoris or myocardial infarction by sex at 20-year followup, 32:table 1

CORONARY ATTACK, Continued
  criteria for,
    in 16-year followup, 26:18
    in 18-year followup, 30:18
    in life tables, 25:15, 32:10
  fitted probability of development, 27:figure 3, 27:figure 4
  following uncomplicated angina pectoris, 32:table II-4, 32:table III-4, 32:figure V-4
  incidence in 14-year followup, 6:table 6-8, 7:table 7-8, 8:table 8-A-7, 8:table 8-C-8
  incidence in 16-year followup, 27:table 7, see guide 5, guide 6
  incidence in 18-year followup, see guide 7
  life table for mortality following coronary attack, 25:table 2A, 25:table 2B, 25:figure 2A
  life tables for, in total Framingham study population, 32:table IV-5
  population at risk of, 8:table 8-B-8
  regression coefficient by 19 characteristics for men and women at 16-year followup, 27:table 15, 27:table 16
  t-values for contribution of additional characteristics to discrimination of, by age and sex at 16-year followup, 27:table 12

CORONARY HEART DISEASE (CHD)
  see also ANGINA PECTORIS;
    CORONARY ATTACK;
    CORONARY INSUFFICIENCY;
    MYOCARDIAL INFARCTION;
    MYOCARDIAL INFARCTION, UNRECOGNIZED
  as a risk factor for another event, 27:34-41
  change in measured characteristics and 5-year mortality in men free of, 32:table VI-12
  coefficients of risk of, estimated by Duncan-Walker procedure, 27:table ii

CORONARY HEART DISEASE (CHD), Continued

- criteria for,
  - in 14-year followup, 8:8-criteria-1
  - in 16-year followup, 26:17
  - in 18-year followup, 30:17
  - in life tables, 25:12, 32:9-12
- discriminant analysis, 23:table 23-A, see also guide 4
- events following CHD, definition of, 32:9-12
  - rules for dating occurrence of end point events, 32:13-14
- experience in 14-year followup of 82 persons with preexisting coronary heart disease, 8:table 8-21
- fatal vs. nonfatal, discriminant statistics, 23:table 23-C
- first definite manifestation occurring in 14-year followup, 8:table 8-23, 8:table 8-24
- fitted probability of development, 16-year followup, 27:figure 1 through figure 4
- in relation to diet, 24:table 24
- incidence by decile of risk, 27:table 17, 27:figure 5
- incidence following other coronary heart disease, 27:table 21
- incidence in relation to diet in Framingham diet study, 24:13-14
- incidence in 14-year followup, 6:table 6-1, 7:table 7-1, 8:table 8-22, 8:table 8A-1, 8:table 8C-1, see also guide 3, guide 4
- incidence in 16-year followup, 27:table 5, see also guide 5, guide 6

CORONARY HEART DISEASE (CHD), Continued

- incidence in 16-year followup, multivariate analysis of factors related to, 27:1-42, 27:table 1 through table 4
  - blood pressure, 27:7-8
  - cigarette smoking, 27:10-11
  - glucose intolerance, 27:9-10
  - left ventricular hypertrophy by ECG, 27:11-13
  - other characteristics, 27:25-32
  - serum cholesterol, 27:8-9
  - sex differentials, 27:21-22
  - t-values for contribution of additional characteristics, 27:table 10
- incidence in 18-year followup, see guide 7
- life tables for CHD in total Framingham Study population 32:table IV-4
- life tables for men and women at 16-year followup, 25:table 1A, 25:table 1B
- life tables for mortality following coronary heart disease, 25:figure 1A, 25:figure 1B, 25:figure 1C
- morbidity after, 32:3
- mortality due to, see CORONARY HEART DISEASE DEATH
- nomogram of CHD risk by level of serum cholesterol and systolic blood pressure:
  - 40 years of age, 23:figure 23-24, 23:figure 23-30
  - 45 years of age, 23:figure 23-25, 23:figure 23-31
  - 50 years of age, 23:figure 23-26, 23:figure 23-32
  - 55 years of age, 23:figure 23-27, 23:figure 23-33
  - 60 years of age, 23:figure 23-28, 23:figure 23-34
  - 65 years of age, 23:figure 23-29, 23:figure 23-35

CORONARY HEART DISEASE (CHD), Continued
  number of persons lost due to moving who developed new coronary disease within 14-year followup, 2:table 6
  number of persons lost to examination while still living in Framingham who developed new coronary disease within 14-year followup, 2:table 7
  other than angina pectoris: see CORONARY ATTACK
  population at risk, 14-year followup, 8:table 8-B-1
  prediction of, 27:32-34
  prevalence at exams 1-7 by level of following characteristics:
    abnormal ECG, 9:table 9-A-14, 9:table 9-B-14
    alcohol consumption per month, 9:table 9-A-1, 9:table 9-B-1
    blood sugar, 9:table 9-A-4, 9:table 9-B-4
    blood uric acid, 9:table 9-A-11, 9:table 9-B-11
    body weight, 9:table 9-A-13, 9:table 9-B-13
    cigarettes smoked, 9:table 9-A-6, 9:table 9-B-6
    diastolic blood pressure by first examiner, 9:table 9-A-3, 9:table 9-B-3
    Framingham relative weight, 9:table 9-A-7, 9:table 9-B-7
    generalized cardiac enlargement by x-ray, 9:table 9-A-20, 9:table 9-B-20
    heart enlargement by x-ray, 9:table 9-A-21, 9:table 9-B-21
    hematocrit, 9:table 9-A-8, 9:table 9-B-8
    hemoglobin, 9:table 9-A-9, 9:table 9-B-9
    left ventricular hypertrophy by ECG, 9:table 9-A-15, 9:table 9-B-15

CORONARY HEART DISEASE (CHD), Continued
- prevalence, Continued
    - left ventricular hypertrophy by x-ray, 9:table 9-A-22, 9:table 9-B-22
    - nonspecific T-wave abnormality by ECG, 9:table 9-A-16, 9:table 9-B-16
    - serum cholesterol, 9:table 9-A-5, 9:table 9-B-5
    - serum phospholipids, 9:table 9-A-10, 9:table 9-B-10
    - smoking now, 9:table 9-A-17, 9:table 9-B-17
    - systolic blood pressure by first examiner, 9:table 9-A-2, 9:table 9-B-2
    - urine albumin, 9:table 9-A-18, 9:table 9-B-18
    - urine sugar, 9:table 9-A-19, 9:table 9-B-19
    - vital capacity, 9:table 9-A-12, 9:table 9-B-12
- probability of development by level of risk factors, 28:table 1
- probability of development of, 27:appendix B
    - probability of development in 2 years, 27:table 1B-1, 27:table 1B-2
    - probability of development in 4 years, 27:table 2B-1, 27:table 2B-2
    - probability of development in 6 years, 27:table 3B-1, 27:table 3B-2
    - probability of development in 8 years, 27:table 4B-1, 27:table 4B-2
- probability of development of, at lowest and highest combination of risk factors, 27:table i
- regression coefficient by 19 characteristics, 27:table 15, 27:table 16
- regression equations for, by sex and age at 16-year followup, 27:table 20
- risk of within 8 years, 28:appendix B
- separate manifestations of, 23:15-17

CORONARY HEART DISEASE DEATH
- criteria for,
    - in 14-year followup, 8:8-criteria-2
    - in 16-year followup, 26:20
    - in 18-year followup, 30:20
    - in life table analysis, 32:3, 32:9
- discriminant analysis, 23:table 23-M, see also guide 4
- end point event after uncomplicated angina pectoris or myocardial infarction by sex at 20-year followup, 32:table 1
- goodness of fit statistics in pooling project, 31:table 30
- incidence in 14-year followup, see guide 3, guide 4
- incidence in 16-year followup, see guide 5
- incidence in 18-year followup, see guide 7
- logistic coefficients by study and risk factor in pooling project, 31:table 28
- logistic coefficients for ECG abnormalities in studies of pooling project, 31:table 33
- multiple logistic analysis in relation to risk factors in studies of pooling project, 31:table 19, 31:table 20, 31:table 23, 31:table 24
- multivariate logistic coefficients by study, pooling project, 31:table 29
- nonsudden death, 30:18
    - criteria for, 28:9, 30:18
    - discriminant analysis, 23:table 23-G
    - incidence in 14-year followup, 6:table 6-16, 7:table 7-16, 8:table 8-A-16, 8:table 8-C-16
    - incidence in 16-year followup, see guide 5
    - incidence in 18-year followup, see guide 7
    - regression coefficient by 19 characteristics, 27:table 15, 27:table 16

CORONARY HEART DISEASE DEATH, Continued
- rate per 1,000 for 12 years by study in pooling project, 31:table 7
- regression coefficient by 19 characteristics, 27:table 15, 27:table 16
- risk deciles, in pooling project, 31:table 25, 31:table 27, 31:table 31
- risk factor averages, in cases and noncases, 31:table 14, 31:table 15
- sudden death:
  - criteria for, 28:9, 30:21, 32:8
  - definition of, 32:9
  - discriminant analysis, 23:table 23-F
  - following uncomplicated angina pectoris, 32:table II-2, 32:table III-2, 32:figure V-2
  - incidence in 14-year followup, 6:table 6-15, 7:table 7-15, 8:table 8-A-15, 8:table 8-C-15
  - incidence in 16-year followup, see guide 5
  - incidence in 18-year followup, see guide 7
  - life tables in total Framingham study population, 32:table IV-2
  - regression coefficient by 19 characteristics, 16-year followup, 27:table 15, 27:table 16
  - unexpected death, regression coefficient by 19 characteristics, 27:table 15, 27:table 16
- univariate logistic analysis in relation to risk factors in studies of pooling project, 31:table 16, 31:table 18

CORONARY INSUFFICIENCY
- criteria for, 28:8, 30:20
- definition as end point event following coronary heart disease, 32:10

CORONARY INSUFFICIENCY, Continued
  incidence in 14-year followup, 6:table 6-5, 7:table 7-5,
    8:table 8-A-5, 8:table 8-C-5
  incidence in 18-year followup, see guide 7
  population at risk by sex, age at exam 1, and exam
    interval at 14-year followup, 8:table 8-B-5

CORRELATION COEFFICIENTS
  between exam correlation, 29:table C-1 through table C-23
  characteristics at exam 2, 5:table 5-1 through table 5-26,
    see guide 2
  of diet characteristics, see FRAMINGHAM DIET STUDY

CVA: see CEREBROVASCULAR ACCIDENT

DEATH: see MORTALITY

DEATH, SUDDEN: see CORONARY HEART DISEASE DEATH

DECILES OF RISK
  in pooling project, 31:table 25 through table 27
  14-year followup, 23:9-10
  16-year followup, 27:table 17 through table 20, 27:figure 5

DIABETES MELLITUS
  diagnosis of, 29:21-23, 30:38-39
  incidence of disease according to, see guide 5,
    guide 7
  percent agreement between 2 exams, 29:table C-23
  percent prevalence, 29:table 23, 29:table A-23,
    29:table B-23

DIASTOLIC BLOOD PRESSURE: see BLOOD PRESSURE, DIASTOLIC

DIET, see also CHOLESTEROL, DIETARY;
FATS, DIETARY;
FRAMINGHAM DIET STUDY;
PROTEINS, DIETARY
- in regulation of serum cholesterol, 24:1-12
- regression of specified diet characteristics on serum cholesterol in Framingham diet study, 24:table 21
- relation to incidence of coronary heart disease in Framingham diet study, 24:13-14

DISCRIMINANT FUNCTION
- 14-year followup, 9:introduction-5, 23:23-55, 23:table 23-A through table 23-O, 23:table 23-A-1.1 through table 23-B-13.2
- 16-year followup, 27:25-27
  - between diseases, 27:appendix D

DISTRIBUTION, FREQUENCY: see guide no.7

ELECTROCARDIOGRAPHIC ABNORMALITIES
see also INTRAVENTRICULAR CONDUCTION DEFECT;
LEFT VENTRICULAR HYPERTROPHY BY ECG
- atrial fibrillation, 29:15
- atrial flutter, 29:15-16
- atrioventricular conduction disturbance, 29:15
- correlation with other characteristics, see guide 2
- definition of, 29:14-16
- distribution of levels of ECG abnormalities at exams 1-7, 9:table 9-A-14, 9:table 9-B-14
- in participants in studies of pooling project, 31:table 32
- incidence of disease according to, see guide 3
- intraventricular conduction defect with QRS interval more than 0.11 second, 29:17-18
- logistic coefficients for, in pooling project, 31:table 33

ELECTROCARDIOGRAPHIC ABNORMALITIES, Continued
  myocardial infarction, 29:16, see also MYOCARDIAL INFARCTION
    average 2-year incidence per 10,000 by sex and age at beginning of 2-year interval at 14-year followup, 7:table 7-3
    population at risk by sex, age at exam 1, and exam interval at 14-year followup, 8:table 8-B-3
    smoothed average annual incidence rate per 1,000 by age and sex at 14-year followup, 6:table 6-3
    2-year incidence by exam interval, sex and age at exam 1, 14-year followup, 8:table 8-A-3
    2-year incidence per 10,000 by sex, age at exam 1, and time of first appearance, 14-year followup, 8:table 8-C-3
  nonspecific T-wave or ST-segment, see NONSPECIFIC T OR ST ABNORMALITIES (ECG)
  percent abnormal at exams 1-7, 4:table 4-18, see also guide 1
  percent abnormal at exams 1-10, 29:table 15
  percent abnormal exams 1-10, 29:table A-15, 29:table B-15
  percent agreement between 2 exams, 29:table C-15

ELECTROCARDIOGRAPHY (ECG)
  determination of ventricular rate and pulse rate, 29:10

EXAMINATION
  date for exams 1-7, 2:table 8

FATS, DIETARY
  daily intake in Framingham diet study, 24:8, 24:figure 12
    animal fat intake, 24:figure 14
    animal fat intake and dietary cholesterol, regression of serum cholesterol on, 24:table 19

FATS, DIETARY, Continued
  daily intake, Continued
      animal fat intake in relation to dietary cholesterol intake, influence on mean serum cholesterol level, 24:table 18
      animal fat intake in relation to mean serum cholesterol level, 24:table 13
      dietary percent fat from animal sources in relation to mean serum cholesterol level, 24:table 14
      intake per pound of body weight, 24:figure 13
      mean value of average daily intake for each 3-month period from January 1957 to September 1960 for men and women, 24:figure 3, 24:figure 4
      percent calories from fat, 24:figure 16
      percent from animal sources, 24:figure 17
      plant fat in daily intake, 24:figure 15
      ratio of intake of plant to animal fat, influence on mean serum cholesterol level, 24:table 15
      relation to mean serum cholesterol level, 24:table 12

FATTY ACIDS
  polyunsaturated/saturated ratio in daily intake in Framingham diet study, 24:figure 18

FOLLOWUP
  consistency in measurements over time, 29:44-53
  examination dates for exams 1-7, 2:table 8
  length of incidence followup:
      14 years, section 6 through section 23
      16 years, section 26, section 27
      18 years, section 28, section 30
      20 years, section 32

FOLLOWUP, Continued
  loss in cohort due to moving, disability and refusal, 2:2c-1 through 2c-2
  number and percent receiving exam 7 and exam 8, 2:table 2 through 4
  number of persons lost due to moving, 2:table 6
  number of persons lost to examination while still living in Framingham, 2:table 7
  number of persons not receiving exam 8 according to last biennial examination received, 2:table 5
  number surviving in cohort and number receiving examination at each of first 8 examinations, 2:table 1
  reexamination at 2-year intervals, 2:2a-1
  repeated clinic examination, 2:2b-1 through 2b-3
  response to initial examination, 1:table 1-1, table 1-2

FRAMINGHAM DIET STUDY
  animal fat in daily intake, 24:figure 14
  animal protein in daily intake, 24:figure 10
  calories in daily intake, 24:figure 7
  calories in daily intake per pound per body weight, 24:figure 8
  cholesterol in daily intake, 24:figure 20
  correlation of calories with some other characteristics of average daily intake of food by sex and age, 24:table 5
  correlation of serum cholesterol with some characteristics of average daily intake of food by age and sex, 24:table 6, 24:appendix table
  daily caloric intake by physical activity index and body weight, 24:table 9
  diet and regulation of serum cholesterol, 24:1-15
  exclusion from dietary sample because of preexisting disease, 24:table 1

FRAMINGHAM DIET STUDY, Continued

- fat in daily intake, 24:figure 12
- fat in daily intake per pound of body weight, 24:figure 13
- iron in daily intake, 24:figure 19
- mean and standard deviation of some characteristics of average daily intake of food, by sex, 24:table 3
- mean daily iron intake at specified levels of blood hemoglobin, 24:table 23
- mean of some characteristics of average daily intake of food by age for men and women, 24:table 4
- mean of some characteristics of average daily intake of food by serum cholesterol level, 24:table 20
- mean serum cholesterol according to daily intake of:
  - animal fat, 24:table 13
  - animal fat and cholesterol, 24:table 18
  - caloric intake, 24:table 7
  - caloric intake per pound of body weight, 24:table 8
  - fat, 24:table 12
  - percent fat from animal sources, 24:table 14
  - physical activity index and daily caloric intake, 24:table 10
  - ratio of complex to simple carbohydrates in food, 24:table 16
  - ratio of plant to animal fat, 24:table 15
- mean value of average daily caloric intake for each 3-month period from January 1957 to September 1960 for men and women, 24:figure 1, figure 2
- mean value of average daily fat intake for each 3 month period from January 1957 to September 1960 for men and women, 24:figure 3, figure 4
- mean value of body weight for each 3-month period from January 1957 to September 1960 for men and women, 24:figure 5, figure 6

FRAMINGHAM DIET STUDY, Continued
- mean values for specified nutrient measurements for persons who developed coronary heart disease subsequent to their diet interviews, by sex, 24:table 24
- measurement of diet in, 24:3-4
- percent calories from fat, 24:figure 16
- percent fat from animal sources, 24:figure 17
- plant fat in daily intake, 24:figure 15
- plant protein in daily intake, 24:figure 11
- polyunsaturated/saturated fatty acid ratio in daily intake, 24:figure 18
- protein in daily intake, 24:figure 9
- regression of mean weight and weight change on serum cholesterol, 24:table 22
- regression of serum cholesterol level on physical activity index, daily caloric intake, and Framingham relative weight, 24:table 11
- regression of serum cholesterol on daily intake of animal fat and dietary cholesterol, 24:table 19
- regression of specified diet characteristics on serum cholesterol, 24:table 21
- relationship of diet to coronary heart disease incidence in, 24:13-14
- relationship of dietary iron and blood hemoglobin in, 24:12-13
- summary description of dietary sample in, 24:table 2
- usual intake in, 24:4-12
  - caloric balance, 24:6-7
  - dietary cholesterol, 24:8-9
  - energy balance, 24:10-12
  - intake of complex to simple carbohydrates, 24:8
  - level of fat intake, 24:8
  - protein intake, 24:8

FRAMINGHAM RELATIVE WEIGHT, see also BODY WEIGHT; METROPOLITAN RELATIVE WEIGHT
  as discriminator of cardiovascular disease, 23:1-54
  computation of, 29:10-11
  correlation between 2 exams, 29:table C-9
  correlation with other characteristics, see guide 2
  correlation with serum cholesterol level in Framingham diet study, 24:table 11
  correlation with physical activity, 24:10
  correlation with calories/day, 24:10
  discriminant analysis in following events:
    see also guide 4
      brain infarction, 23:table 23-I
      cerebrovascular accident, 23:table 23-H
      congestive heart failure, 23:table 23-K
      coronary heart disease, 23:table 23-A
      death from all causes, 23:table 23-L
      death from coronary heart disease, 23:table 23-M
      intermittent claudication, 23:table 23-J
      myocardial infarction, 23:table 23-D
      noncardiovascular death, 23:table 23-O
      nonsudden death from coronary heart disease, 23:table 23-G
      other cardiovascular death, 23:table 23-N
      sudden death from coronary heart disease, 23:table 23-F
      uncomplicated angina pectoris, 23:table 23-E
  discriminant statistics in fatal vs. nonfatal coronary heart disease, 23:table 23-C
  discriminant statistics in myocardial infarction vs. angina pectoris, 23:table 23-B
  distribution at exams 1-7, 9:table 9-A-7, 9:table 9-B-7
  incidence of disease according to, see guide 3, guide 4, guide 5

FRAMINGHAM RELATIVE WEIGHT, Continued
  mean level by age in men developing and not developing coronary heart disease in 4-year intervals at 14-year followup, 23:figure 23-5
  mean value at exam 1 by response to exam 10, 29:table 9
  mean value at exams 1-7, 4:table 4-11
  mean values by age and sex for exams 1-10, 29:table A-9, 29:table B-9
  mean values according to disease status,
    men, 23:figure 23-6, 23:figure 23-12, 23:figure 23-18
    women, 23:figure 23-9, 23:figure 23-15, 23:figure 23-21
  mean weight by time of determinations, exams 1-7, 23:figure 23-1
  standard errors at exams 1-7, 3:table 3-11
  variation, intraindividual, 29:table 9 appendix 2

FRAMINGHAM STUDY
  bibliography of, 1:1i-1 through 1i-7, 25:33-36, 28:1-15, 29:1-15, 30:1-15, 31:1-18, 32:147
  community arragements for, 1:1d-1 through 1d-3
  early history of, 1:1c-1 through 1c-2, 32:3-4
  focus on arteriosclerotic and hypertensive disease, 1:1b-2
  geographic coverage of, 1:1b-5
  laboratory and technical personnel, 1:1j-2 through 1j-3
  mortality in early years of, 1:1f-4 through 1f-5
  mortality in later years of, 1:1f-6 through 1f-8
  nonresponse of participants in, 1:1f-2
  nurses, 1:1j-2
  nutritionists, 1:1j-3
  other personnel, 1:1j-4 through 1j-5
  plan of study, 1:1b-2 through 1b-6
  population alive at beginning of each exam interval, 8:table 8-B-14 through table 8-B-20

FRAMINGHAM STUDY, Continued
  population to be studied, 1:1b-4
  protocol of, 1:1b-3 through 1b-4
  rationale of, 1:1b-1 through 1b-6
  sample response in, 1:1f-1 through 1f-5
  sampling plan of, 1:1e-1 through 1e-3
  staff physicians, 1:1j-1 through 1j-2
  statistical personnel, 1:1j-3 through 1j-4
  technical advisory committee of, 1:1c-3 through 1c-4

GLUCOSE IN URINE: see URINE GLUCOSE

GLUCOSE INTOLERANCE
  demonstration in subjects, 30:40
  description of, 28:16
  incidence of disease according to, see guide 5, guide 6, guide 7
  probability of cardiovascular diseases
    by level of glucose intolerance:
    16-year followup, 27:tables 1B-4B
    18-year followup, 28:tables 1-5
  regression coefficients for cardiovascular diseases
    on glucose intolerance 16-year followup,
    27:table 1 through table 4

GLYCOSURIA: see URINE GLUCOSE

HEART DISEASES, see also CORONARY HEART DISEASE;
    HEART FAILURE, CONGESTIVE
  diagnostic efficiency, 1:1b-2

HEART ENLARGEMENT
  see also LEFT VENTRICULAR HYPERTROPHY BY ECG;
           LEFT VENTRICULAR HYPERTROPHY BY X-RAY
  definite by x-ray, 29:20-21, 30:32-34
    age trends in, 29:figure 11
    correlation with other characteristics, see guide 2
    incidence of disease according to, see guide 3, guide 5, guide 7
    percent agreement between 2 exams, 29:table C-21
    percent at exam 1 by response to exam 10, 29:table 21
    percent at exams 1-7, 4:table 4-25, see also guide 1
    percent at exams 1-10, 29:table A-21, 29:table B-21
  distribution of heart enlargement at exams 1-7, 9:table 9-A-21, 9:table 9-B-21
  generalized by x-ray, 29:19
    correlation with other characteristics, see guide 2
    distribution of generalized enlargement at exams 1-7, 9:table 9-A-20, 9:table 9-B-20
    incidence of disease according to, see guide 3,
    percent agreement between 2 exams, 29:table C-19
    percent at exam 1 by response to exam 10, 29:table 19
    percent at exams 1-7, 4:table 4-24, see also guide 1
    percent at exams 1-10, 29:table A-19, 29:table B-19

HEART FAILURE, CONGESTIVE (CHF)
  see also HYPERTENSIVE HEART FAILURE
- criteria for,
  - in 14-year followup, 8:8-criteria-4
  - in 16-year followup, 26:22-23
  - in 18-year followup, 30:23-24
  - in life tables, 32:11-12
- discriminant analysis, 23:table 23-K, 23:figure 23-18 through figure 23-23, see guide 4
- end point event after uncomplicated angina pectoris or myocardial infarction by sex at 20-year followup, 32:table 1
- following recognized myocardial infarction, 32:table II-11, 32:figure V-11
- following uncomplicated angina pectoris, 32:table II-6, 32:table III-6, 32:figure V-6
- following unrecognized myocardial infarction, 32:table II-15
- incidence in 14-year followup, 6:table 6-13, 7:table 7-13, 8:table 8-A-13, 8:table 8-C-13, see also guide 3, guide 4
- incidence in 16-year followup, see guide 5
- incidence in 18-year followup, see guide 7
- life tables for, in total Framingham Study population, 32:table IV-8
- life tables for mortality following CHF, 25:table 5-A, 25:table 5-B, 25:figure 5-A, 25:figure 5-B
- population at risk by sex, age at exam 1, and exam interval at 14-year followup, 8:table 8-B-13
- prevalence at exams 1-7
  - by level of following characteristics:
    - abnormal ECG, 9:table 9-A-14, 9:table 9-B-14
    - alcohol consumption per month, 9:table 9-A-1, 9:table 9-B-1

HEART FAILURE, CONGESTIVE (CHF), Continued
  prevalence, Continued
    blood sugar, 9:table 9-A-4, 9:table 9-B-4
    blood uric acid, 9:table 9-A-11, 9:table 9-B-11
    body weight, 9:table 9-A-13, 9:table 9-B-13
    cigarettes smoked, 9:table 9-A-6, 9:table 9-B-6
    diastolic blood pressure by first examiner, 9:table 9-A-3, 9:table 9-B-3
    Framingham relative weight, 9:table 9-A-7, 9:table 9-B-7
    generalized cardiac enlargement by x-ray, 9:table 9-A-20, 9:table 9-B-20
    heart enlargement by x-ray, 9:table 9-A-21 9:table 9-B-21
    hematocrit, 9:table 9-A-8, 9:table 9-B-8
    hemoglobin, 9:table 9-A-9, 9:table 9-B-9
    left ventricular hypertrophy by ECG, 9:table 9-A-15, 9:table 9-B-15
    left ventricular hypertrophy by x-ray, 9:table 9-A-22, 9:table 9-B-22
    nonspecific T-wave abnormality by ECG, 9:table 9-A-16, 9:table 9-B-16
    serum cholesterol, 9:table 9-A-5, 9:table 9-B-5
    serum phospholipids, 9:table 9-A-10, 9:table 9-B-10
    smoking now, 9:table 9-A-17, 9:table 9-B-17
    systolic blood pressure by first examiner, 9:table 9-A-2, 9:table 9-B-2
    urine albumin, 9:table 9-A-18, 9:table 9-B-18
    urine sugar, 9:table 9-A-19, 9:table 9-B-19
    vital capacity, 9:table 9-A-12, 9:table 9-B-12
  regression coefficient by 19 characteristics, 27:table 15, 27:table 16
  relative survival rate, 25:figure 5-C

HEART VENTRICLE, LEFT:
see LEFT VENTRICULAR HYPERTROPHY BY ECG;
LEFT VENTRICULAR HYPERTROPHY BY X-RAY

HEMATOCRIT
age trends for cross-sectional and cohort data for exams 1-10, 29:figure 5
age trends in, 29:35
correlation between 2 exams, 29:table C-5
distribution of levels at exams 1-7, 9:table 9-A-8, 9:table 9-B-8
incidence of disease according to, see guide 3
mean value at exam 1 by response to exam 10, 29:table 5
mean values at exams 1-7, 4:table 4-12, see also guide 1
mean values at exams 1-10, 29:table A-5, 29:table B-5
readings taken, 29:9
standard errors at exams 1-7, 3:tables 3-12
variation, intraindividual, 29:table 5 appendix 2

HEMOGLOBIN
correlation with other characteristics, see guide 2
distribution of levels at exams 1-7, 9:table 9-A-9, 9:table 9-B-9
incidence of disease according to, see guide 3, guide 5
in relation to mean daily iron intake, 24:table 23
level in relation to dietary iron in Framingham diet study, 24:12-13
mean values at exams 1-7, 4:table 4-13, see also guide 1
standard errors at exams 1-7, 3:table 3-13

HISTORY: see FRAMINGHAM STUDY

HYPERTENSION, see also BLOOD PRESSURE, DIASTOLIC;
BLOOD PRESSURE, SYSTOLIC;
HYPERTENSIVE HEART FAILURE
  definite, 29:21
  determination of, 30:31-32
  Framingham study of, rationale, 1:1b-1 - 1b-6
  hypotensive drugs,
    number using at exams 4-10, 29:before p.28
    relation to blood pressure, 29:table B-1B, 29:figure 1b
  incidence of disease according to, see guide 5, guide 7
  percent agreement between 2 exams, 29:table C-22
  percent at exam 1 by response to exam 10, 29:table 22
  percent at exams 1-10, 29:table A-22, 29:table B-22

HYPERTENSIVE HEART FAILURE
  criteria for, 28:10-11
  probability of development according to risk factors, 28:table 4
  risk of within 8 years, 28:appendix B

HYPOTENSIVE DRUGS
  number using at exams 4-10, 29:before p.28
  relation to blood pressure, 29:table B-1B, 29:figure 1b

INCIDENCE OF CARDIOVASCULAR DISEASES AND/OR DEATH
  14-year followup:
    age smoothed average annual incidence, 6:tables 1 through 20
    by levels of characteristics, section 10 through section 22, see also guide 3, guide 4
    observed average 2-year incidence, 7:tables 1 through 20
    observed incidence at each exam, 8:tables 1 through 24

INCIDENCE OF CARDIOVASCULAR DISEASES AND/OR DEATH, Continued
- 16-year followup:
    - age fitted 2-year incidence, 27:table 5 through table 9, 27:figure 1 through figure 4, see also guide 5, guide 6
    - by levels of characteristics, section 26
    - observed average annual rate, section 26
    - observed incidence, 12 year, 14 year, 16 year, section 26
    - observed 2-year incidence, 27:table 5 through table 9
- 18-year followup:
    - by level of characteristic, 30:table 1 through table 14
    - observed average annual incidence, 30:table 1 through table 14

INTERMITTENT CLAUDICATION (IC)
- criteria for,
    - in 14-year followup, 8:8-criteria-3
    - in 16-year followup, 26:21
    - in 18-year followup, 28:9, 30:23
    - in life tables, 25:30
- diagnosis of, 25:30
- discriminant analysis, 23:table 23-J
- following other cardiovascular diseases, 27:table 21
- incidence in 14 year followup, 6:table 6-12, 7:table 7-12, 8:table 8-A-12, 8:table 8-C-12, see also guide 3, guide 4
- incidence in 16-year followup, 27:table 9, see also guide 5, guide 6
- incidence in 16-year followup, multivariate analysis of factors related to, 27:1-42, 27:tables 1 through 4
    - blood pressure, 27:7-8
    - cigarette smoking, 27:10-11

INTERMITTENT CLAUDICATION (IC), Continued
  incidence in 16-year followup, Continued
      glucose intolerance, 27:9-10
      left ventricular hypertrophy by ECG, 27:11-13
      other characteristics, 27:25-32
      serum cholesterol, 27:8-9
      t-values for contribution of additional characteristics, 27:table 14
      variation by atherosclerotic event, 27:table 22-25
      variation of risk relationships by age and sex, 27:13-21
  incidence in 18-year followup, see guide 7
  life tables for mortality following IC, 25:table 8A, 25:figure 8A
  population at risk by sex, age at exam 1, and exam interval at 14-year followup, 8:table 8-B-12
  prevalence at exams 1-7 and population alive at exams 1-7 by sex, age and level of following characteristics:
      abnormal ECG, 9:table 9-A-14, 9:table 9-B-14
      alcohol consumption per month, 9:table 9-A-1, 9:table 9-B-1
      blood sugar, 9:table 9-A-4, 9:table 9-B-4
      blood uric acid, 9:table 9-A-11, 9:table 9-B-11
      body weight, 9:table 9-A-13, 9:table 9-B-13
      cigarettes smoked, 9:table 9-A-6, 9:table 9-B-6
      diastolic blood pressure by first examiner, 9:table 9-A-3, 9:table 9-B-3
      Framingham relative weight, 9:table 9-A-7, 9:table 9-B-7
      generalized cardiac enlargement by x-ray, 9:table 9-A-20, 9:table 9-B-20
      heart enlargement by x-ray, 9:table 9-A-21 9:table 9-B-21
      hematocrit, 9:table 9-A-8, 9:table 9-B-8
      hemoglobin, 9:table 9-A-9, 9:table 9-B-9

INTERMITTENT CLAUDICATION (IC), Continued
  prevalence, Continued
    left ventricular hypertrophy by ECG, 9:table 9-A-15, 9:table 9-B-15
    left ventricular hypertrophy by x-ray, 9:table 9-A-22, 9:table 9-B-22
    nonspecific T-wave abnormality by ECG, 9:table 9-A-16, 9:table 9-B-16
    serum cholesterol, 9:table 9-A-5, 9:table 9-B-5
    serum phospholipids, 9:table 9-A-10, 9:table 9-B-10
    smoking now, 9:table 9-A-17, 9:table 9-B-17
    systolic blood pressure by first examiner, 9:table 9-A-2, 9:table 9-B-2
    urine albumin, 9:table 9-A-18, 9:table 9-B-18
    urine sugar, 9:table 9-A-19, 9:table 9-B-19
    vital capacity, 9:table 9-A-12, 9:table 9-B-12
  probability of development according to risk factors, 28:table 2
  probability of development in 2 years, 16-year followup, 27:figure 1, 27:figure 2
  regression equations for, 16-year followup, 27:table 20
  risk deciles, 27:table 19, 27:figure 5
  risk of within 8 years, 28:appendix B
  smoothed average annual incidence rate per 1,000 by age and sex at 14-year followup, 6:table 6-12

INTRAVENTRICULAR CONDUCTION DEFECT
  age trends in prevalence for cross-sectional and cohort data for exams 1-10, 29:figure 10
  incidence of disease according to, see guide 7
  percent agreement between 2 exams, 29:table C-17
  percent at exam 1, by response to exam 10, 29:table 17
  percent at exams 1-10, 29:table A-17, 29:table B-17
  with QRS interval more than 0.11 second, 29:17-18, 30:36-37

IRON
- daily intake, 24:figure 19
- dietary, relation to blood hemoglobin, 24:12-13
- mean daily intake at specified levels of blood hemoglobin, 24:table 23

LEFT VENTRICULAR HYPERTROPHY (LVH) BY ECG
- age trends for exams 3-10, 29:figure 9
- correlation with other characteristics, see guide 2
- description of, 28:15-16, 29:17, 30:34-35
- distribution of LVH at exams 1-7, 9:table 9-A-5, 9:table 9-B-5
- incidence of disease according to, see guide 3, guide 5, guide 6, guide 7
- percent agreement between two exams, 29:table C-16
- percent at exam 1, by response to exam 10, 29:table 16
- percent at exams 1-7, 4:table 4-19, see also guide 1
- percent at exams 1-10, 29:table A-16, 29:table B-16
- probability of cardiovascular diseases according to LVH,
  - 16-year followup, 27:tables 1B-4B
  - 18-year followup, 28:tables 1-5
- regression coefficients for cardiovascular disease, on IVH-ECG
  - 16-year followup, 27:table 1-4

LEFT VENTRICULAR HYPERTROPHY (LVH) BY X-RAY
- correlation with other characteristics, see guide 2
- description of, 29:19-20, 30:33-34
- distribution of LVH at exams 1-7, 9:table 9-A-22, 9:table 9-B-22
- incidence of disease according to, see guide 3
- percent agreement between 2 exams, 29:table C-20

LEFT VENTRICULAR HYPERTROPHY (LVH) BY X-RAY, Continued
  percent at exam 1 by response to exam 10, 29:table 20
  percent at exams 1-7, 4:table 4-26, see also guide 1
  percent at exams 1-10, 29:table A-20, 29:table B-20

LIFE TABLES
  column definitions in, 25:6-11
  for cardiovascular disease following:
    angina pectoris, 32:table II, 32:table III
    myocardial infarction, 32:table II, 32:table III
  for mortality following:
    brain infarction, 25:table 7A, 25:table 7B 25:table 7B
    cerebrovascular accident, 25:table 6A, 25:table 6B
    congestive heart failure, 25:table 5A, 25:table 5B
    coronary attack, 25:table 2A, 25:table 2B
    coronary heart disease, 25:table 1A, 25:table 1B
    intermittent claudication, 25:table 8A
    myocardial infarction, 25:table 4A, 25:table 4B, 32:table II, 32:table III
    uncomplicated angina pectoris, 25:table 3A, 32:table II, 32:table III
  life table methodology, 32:15-24, 25:6-11
  methodology for analyzing factors associated with survival, 32:25-31
  rules for dating occurrence of baseline disease, 32:13

LIPIDS: see CHOLESTEROL, DIETARY; SERUM CHOLESTEROL; SERUM PHOSPHOLIPIDS

LOGISTIC FUNCTION ("WALKER-DUNCAN")
  application to other studies, section 31
  description of, 26:11-16, 30:13-16
  use in 16-year followup, section 26
      multivariate, 27:1-4
  18-year followup, 28:17-21, 28:appendix 2, 30:table 1
    through table 14

LVH BY ECG: see LEFT VENTRICULAR HYPERTROPHY BY ECG

LVH BY X-RAY: see LEFT VENTRICULAR HYPERTROPHY BY X-RAY

MEAN VALUES OF CHARACTERISTICS
  at exams 1-7, 3:table 3-1 through table 3-17, see guide 1
    4:table 4-1 through table 4-17
  at exams 1-10, 29:table A-1 through table A-11
  by disease status, 23:figure 23-5 through figure 23-23
  by response to exam 10, 29:appendix 1
  by time of determination, 23:figure 23-1 through figure 23-4

MEAN VALUES OF DIET: see FRAMINGHAM DIET STUDY

METROPOLITAN RELATIVE WEIGHT, see also BODY WEIGHT
  computation of, 29:11-12, 30:29-30
  correlation between 2 exams, 29:table C-10
  incidence of disease according to, see guide 7
  mean value at exam 1 by response to exam 10, 29:table 10
  mean values at exams 1-10, 29:table A-10, 29:table B-10
  variation, intraindividual, 29:table 10 appendix 2

MI: see MYOCARDIAL INFARCTION

MISSING VALUES FOR 23 CHARACTERISTICS 29:6

MORTALITY, see also CARDIOVASCULAR DISEASE DEATH; CORONARY HEART DISEASE DEATH
- characteristics related to mortality in those:
  - free of coronary heart disease, 32:tables VI-10 through VI-13
  - with angina pectoris, 32:table VI-1 through table VI-4 32:table VI-10 through table VI-13
  - with myocardial infarction, 32:table VI-5 through table VI-13
- compared to Framingham town and Massachusetts State, 1:table 1-3
- compared to Framingham town and U.S., 1:table 1-4
- compared to U.S., 1:tables 1-5 through tables 1-7
- criteria for reporting death,
  - in 14-year followup, 8:8-criteria-4
  - in 16-year followup, 26:23
  - in 18-year followup, 30:24-25
  - in life tables, 32:9
- discriminant analysis, 23:table 23-L, see also guide 4
- following recognized myocardial infarction, 32:table II-8, 32:table II-17, 32:table III-8, 32:figure V-8
- following uncomplicated angina pectoris, 32:table II-1, 32:table III-1, 32:figure V-1
- following unrecognized myocardial infarction, 32:table II-13

MORTALITY, Continued
- from cancer:
  - incidence in 14-year followup, 6:table 6-19, 7:table 7-19, 8:table 8-A-19, 8:table 8-C-19
- from cardiovascular disease:
  - average 2-year death rates per 10,000 by sex and age at beginning of 2-year interval at 14-year followup, 7:table 7-18
  - incidence in 14-year followup, see also guide 3, guide 4
    - by exam: number of cases, 8:table 8-A-18
      - population at risk, 8:table 8-B-18
      - rate, 8:table 8-C-18
    - observed incidence, 7:table 7-18
    - smoothed average, 6:table 6-18
  - incidence in 16-year followup, see guide 5
  - incidence in 18-year followup, see guide 7
- from cerebrovascular accidents:
  - incidence in 14-year followup:
    - by exam: number of cases, 8:table 8-A-17
      - population at risk, 8:table 8-B-17
      - rate, 8:table 8-C-17
    - observed incidence, 7:table 7-17
    - smoothed average, 6:table 6-17
- from noncardiovascular diseases:
  - discriminant analysis, 23:table 23-O
- from other cardiovascular diseases:
  - discriminant analysis, 32:table 23-N

MORTALITY, Continued

- from other causes:
  - incidence in 14-year followup, see also guide 3, guide 4
    - by exam: number of cases, 8:table 8-A-20
      - population at risk, 8:table 8-B-20
      - rate, 8:table 8-C-20
    - observed incidence, 7:table 7-20
    - smoothed average, 6:table 6-20
- from specified causes according to response and sex of drawn sample for years 1951-1952, 1:table 1-8
- in early years of Framingham study, 1:1f-4 - 1f-5
- in later years of Framingham study, 1:1f-6 - 1f-8
- in nonrespondents to exam 1, 1:table 1-3, 1:table 1-7,
- in sample for years 1953-1966, 1:table 1-5
- in sample group and for volunteers for years 1953-1966, 1:table 1-6
- incidence in 14-year followup, 6:table 6-14, 7:table 7-14, 8:table 8-A-14, 8:table 8-C-14, see also guide 3, guide 4
- incidence in 16-year followup, see guide 5, guide 6
- incidence in 18-year followup, guide 7
- life tables for death in total Framingham study population, 32:table IV-1
- in pooling project:
  - actual and expected number by decile of risk using different multivariate logistics, 31:table 26
  - averages for cases and noncases in relation to risk factors, 31:table 14
  - goodness of fit statistics for actual and expected numbers, by study, event and set of risk factors, 31:table 30

MORTALITY, Continued
  in pooling project, Continued
    multiple logistic analysis in relation to risk factors, 31:table 21, 31:table 22
    percentage of cases assigned to upper decile of risk by event and study, 31:table 31
    standardized multivariate logistic coefficients by study, event and specified set of risk factors, 31:table 29
    standardized univariate and multivariate logistic coefficients for ECG abnormalilties in, 31:table 33
    standardized univariate logistic coefficients by study and risk factor, 31:table 28
    univariate logistic analysis in relation to risk factors, 31:table 17
  of sample nonrespondents by sex for ages 45-69 for years 1953-1966, 1:figure 1-2
  of sample respondents by sex for ages 45-69 for years 1953-1966, 1:figure 1-1
  rate per 1,000 for 12 years by study in pooling project, 31:table 7
  rates by sex for ages 35-59 for Framingham sample and town and for U. S. whites for years 1950-1952 and 1953-1956, 1:table 1-4
  rates in
    14-year followup, see guide 3
    16-year followup, see guide 5
    18-year followup, see guide 7
  regression coefficient by 19 characteristics for men and women at 16-year followup, 27:table 15, 27:table 16
  smoothed average annual death rates per 1,000 by age and sex at 14-year followup, 6:table 6-14

MYOCARDIAL INFARCTION (MI)
- averages for cases and noncases in relation to risk factors in pooling project, 31:table 13
- cardiovascular diseases and death after, 20-year followup, 32:1-103
  - life table methodology, 32:15-24
  - methodology for analyzing factors associated with survival, 32:25-31
  - rules for dating occurrence of baseline disease, 32:13
- change in measured characteristics and 5-year mortality in men after, 32:table VI-8a, 32:table VI-8b, 32:table VI-12
- characteristics associated with prognosis, 32:table VI
- criteria for,
  - in 14-year followup, 8:8-criteria-1
  - in 16-year followup, 26:18-19
  - in 18-year followup, 28:7-8, 30:18-20
  - in life tables, 25:20, 32:9
- death rate per 1,000 for 12 years by study in pooling project, 31:table 7
- designated by ECG, 29:16
- discriminant analysis, 23:table 23-D, 23:figure 23-6, 23:figure 23-7, 23:figure 23-8, 23:figure 23-12, 23:figure 23-13, 23:figure 23-14, see also guide 4
- following uncomplicated angina pectoris, by age, sex and interval of occurrence, 32:table II-5, 32:table III-5, 32:figure V-5
- goodness of fit statistics for actual and expected numbers, by study, event and set of risk factors in pooling project, 31:table 30
- incidence in 14-year followup, see also guide 3, guide 4

MYOCARDIAL INFARCTION (MI), Continued
  incidence in 14-year followup, Continued
      by exam: number of cases, 8:table 8-A-2 through table 8-A-4
          population at risk, 8:table 8-B-2 through table 8-B-4
          rate, 8:table 8-C-2 through table 8-C-4
      observed incidence, 7:table 7-2 through table 7-4
      smoothed average, 6:table 6-2 through table 6-4
  incidence in 16-year followup, see guide 5
  incidence in 18-year followup, see guide 7
  life tables for, in total Framingham Study population, 32:table IV-7
  life tables of following end points in populations with recognized myocardial infarction:
    angina pectoris, 32:table II-9, 32:table III-9, 32:figure V-9
    congestive heart failure, 32:table II-11, 32:table III-11, 32:figure V-11
    death, 25:table 4A, 25:table 4B, 25:figure 4A, 25:figure 4B, 32:table II-8, 32:table III-8, 32:table II-13, 32:table III-13, 32:figure V-8, 32:figure V-13
    second myocardial infarction, 32:table II-10, 32:table III-10, 32:figure V-10
  multiple logistic analysis in relation to risk factors in studies of pooling project, 31:table 19, 31:table 20
  number of persons at risk and number of subsequent end point events at 20-year followup, 32:table 1

MYOCARDIAL INFARCTION (MI), Continued
  regression coefficient by 19 characteristics, 27:table 15, 27:table 16
  relative survival rate for men at exam intervals after, 25:figure 4C
  risk deciles in pooling project, 31:table 25, 31:table 31
  second infarction following recognized myocardial infarction, 32:table II-10, 32:table III-10
  second infarction following unrecognized myocardial infarction, 32:table II-14
  standardized multivariate logistic coefficients by study, event and specified set of risk factors in pooling project, 31:table 29
  standardized univariate and multivariate logistic coefficients for ECG abnormalities in studies of pooling project, 31:table 33
  standardized univariate logistic coefficients by study and risk factor in pooling project, 31:table 28
  univariate logistic analysis in relation to risk factors in studies of pooling project, 31:table 16
  vs. angina pectoris, discriminant statistics, 23:table 23-B

MYOCARDIAL INFARCTION, RECOGNIZED: see MYOCARDIAL INFARCTION

MYOCARDIAL INFARCTION, UNRECOGNIZED
  diseases following unrecognized myocardial infarction:
    cerebrovascular accident, 32:table II-16
    congestive heart failure, 32:table II-15
    death, 32:table II-13
    second myocardial infarction, 32:table II-14
  life tables for death after, 32:table III-12, 32:figure V-12

NEOPLASMS
  as cause of death in drawn sample according to response and sex for years 1951-1952, 1:table 1-8
  incidence in 14-year followup:
    by exam: number of cases, 8:table 8-A-19
      population at risk, 8:table 8-B-19
      rate, 8:table 8-C-19
    observed incidence, 7:table 7-19
    smoothed average, 6:table 6-19

NONSPECIFIC T OR ST ABNORMALITIES (ECG)
  correlation with other characteristics, see guide 2
  definition, 29:18-19, 30:37
  distribution of categories of nonspecific T or ST abnormalities at exams 1-7, 9:table 9-A-16, 9:table 9-B-16
  incidence of disease according to, see guide 3, guide 5, guide 7
  percent abnormal at exams 1-7, 4:table 4-20, see also guide 1
  percent abnormal exam 1 by response to exam 10, 29:table 18
  percent abnormal exams 1-10, 29:table A-18, 29:table B-18
  percent agreement between 2 exams, 29:table C-18

OBESITY: see BODY WEIGHT

ODDS
  relative average odds, 27:3-4, 27:table 1-A through table 5-A

PERSONNEL: see FRAMINGHAM STUDY

PHOSPHOLIPIDS: see SERUM PHOSPHOLIPIDS

PHYSICAL ACTIVITY INDEX
  correlation with serum cholesterol level, 24:table 11
  correlation with caloric intake, 24:11
  correlation with relative weight, 24:10
  in relation to daily caloric intake, 24:table 9
  in relation to mean serum cholesterol, 24:table 10

POOLING PROJECT
  death rate per 1,000 for 12 years by study in, 31:table 7
  description of studies in, 31:table 1
  distribution of risk factors, by study,
    diastolic blood pressure, 31:figure 2
    serum cholesterol, 31:figure 3
    systolic blood pressure, 31:figure 1
  distribution of risk factors in population at risk and cases, by study,
    diastolic blood pressure, 31:table 9
    relative weight, 31:table 12
    serum cholesterol, 31:table 10
    smoking habit, 31:table 8
  goodness of fit statistics for actual and expected numbers, by study, event and set of risk factors in, 31:table 30
  incident events in, 31:6-7
  logistic analysis, disease and risk factors,
    coronary heart disease death, 31:tables 16, 18, 19, 20, 23, 24
    death, all causes, 31:tables 17, 21, 22
    myocardial infarction and coronary heart disease death, 31:tables 16, 19, 20
  mean values and standard deviations of specified risk factors in, 31:table 5

POOLING PROJECT, Continued
  means of risk factors for cases and noncases,
      coronary heart disease death, 31:table 15
      death, all causes, 31:table 14
      myocardial infarction, 31:table 13
  methods of measurement of variables in each study in, 31:table 3
  number of men by age at entry for each study in, 31:table 2
  number of persons and number of events by study with and without exclusions in, 31:table 6
  number of persons by ECG status in studies of, 31:table 32
  other risk factors and end points in, 31:15
  percent of populations in studies with smoking habits, 31:table 4
  percentage of cases assigned to upper decile of risk by event and study in, 31:table 31
  prediction of events using different multivariate logistics,
      coronary heart disease death, 31:table 25, 31:table 27
      death, all causes, 31:table 26
      myocardial infarction, 31:table 25
  risk factor and incidence findings by study in, 31:9-12
  risk factors in, 31:5-6
  standardized multivariate logistic coefficients by study, event, and specified set of risk factors in, 31:table 29
  standardized univariate and multivariate logistic coefficients for ECG abnormalities, by event and study in, 31:table 33
  standardized univariate logistic coefficients by study and risk factor in, 31:table 28
  use of Framingham coefficients to predict event rates in studies of, 31:13-14

POPULATION: see SAMPLE GROUP; VOLUNTEERS

PREDICTING CARDIOVASCULAR DISEASES, see also POOLING PROJECT
  16-year followup, 27:32-34, 27:appendix B
  18-year followup, section 28

PREVALENCE
  characteristics at exams 1-7, 3:table 3-18 through table 3-26, 4:table 4-18 through table 4-26
  characteristics at exams 1-10, 29:table A-12 through table A-23
  disease events at exams 1-7, by level of characteristics, section 9

PROBABILITY OF DISEASE BY LEVEL OF CHARACTERISTIC: see PREDICTING CARDIOVASCULAR DISEASES

PROGNOSIS: see LIFE TABLES

PROTEINS, DIETARY
  daily intake in Framingham diet study, 24:8, 24:figure 9
    animal protein intake, 24:figure 10
    plant protein intake, 24:figure 11

PUBLIC RELATIONS
  early program of Framingham study, 1:1d-3

PULSE RATE
  age trends in, 29:35, 29:figure 7
  correlation between 2 exams, 29:table C-7
  determination from ECG, 29:10
  determination of, 30:30-31
  incidence of disease according to, see guide 7
  mean value at exam 1 by response to exam 10, 29:table 7
  mean values at exams 1-10, 29:table A-7, 29:table B-7
  variation, intraindividual, 29:table 7 appendix 2

RACIAL FACTORS
  U.S. whites, death rates by sex for ages 35-59 for years 1950-1952 and 1953-1956, 1:table 1-4
  U.S. whites, mortality of sample nonrespondents for ages 45-69 for years 1953-1966, 1:figure 1-2
  U.S. whites, mortality of sample respondents for ages 45-69 for years 1953-1966, 1:figure 1-1

RATES: see each disease end point, e.g., CORONARY HEART DISEASE

REGRESSION
  diet characteristics, see FRAMINGHAM DIET STUDY
  logistic function, see LOGISTIC FUNCTION

RELATIVE WEIGHT, see also FRAMINGHAM RELATIVE WEIGHT; METROPOLITAN RELATIVE WEIGHT
  age trends in, 29:36-38
  level according to number of persons and number of specified events in studies of pooling project, 31:table 12

RESPONSE TO EXAMINATIONS, see also FOLLOWUP
  mean values of characteristics by response, section 3, see also guide 1

RESPONSE TO INITIAL EXAMINATION, 1:table 1-1 through table 1-2

RISK FACTORS: see names of specific factors, e.g., BLOOD PRESSURE, SYSTOLIC

RISK HANDBOOKS, 27:appendix B, 28:tables 1-5

SAMPLE GROUP
  deaths from specified causes according to response and sex for years 1951-1952, 1:table 1-8
  drawn sample for ages 30-59, number and percent examined and number not examined, 1:table 1-1
  drawn sample, response and nonresponse by reason, 1:table 1-2
  examination dates for exams 1-7, 2:table 8
  loss due to moving, disability and refusal, 2:2c-1 through 2c-2
  nonresponse of, 1:1f-2
  not taking exam 1, actual and expected deaths by sex for years 1953-1966, 1:table 1-7
  number of persons according to examination status at exam 7 and at exam 8, 2:table 2
  number of persons according to examination status at exam 7 and at exam 8 in relation to number of biennial examinations received, 2:table 3
  number of persons lost due to moving who developed new coronary disease within 14-year followup, 2:table 6
  number of persons not receiving exam 8 according to last biennial examination received, 2:table 5
  number of persons lost to examination while still living in Framingham who developed new coronary disease within 14-year followup, 2:table 7
  number surviving in cohort and number receiving examination at each of first 8 examinations, 2:table 1
  response of, 1:1f-1 through 1f-5
  taking exam 1, actual and expected deaths by sex for years 1953-1966, 1:table 1-6
  total drawn sample, actual and expected deaths by sex for years 1953-1966, 1:table 1-5

SAMPLING
  plan for Framingham study, 1:1e-1 through 1e-3

SERUM CHOLESTEROL
- age trends in, 29:34
- as discriminator of cardiovascular disease, 23:1-54
- average age trends for cross-sectional and cohort data for exams 1-10, 29:figure 3
- correlation between 2 exams for all subjects and for subjects taking exam 10, by sex, 29:table C-3
- correlation with dietary intake, 24:table 6, 24:appendix table
- correlation with other characteristics, see guide 2
- description of, 28:14-15
- determination of, 29:8, 30:27
- diet in regulation of, 24:1-12
- discriminant analysis based on 4-year followup from exams 2, 4 or 6 in following events: (See also guide 4)
  - brain infarction, 23:table 23-I
  - cerebrovascular accident, 23:table 23-H
  - congestive heart failure, 23:table 23-K
  - coronary heart disease, 23:table 23-A
  - coronary heart disease death, 23:table 23-M
  - death from all causes, 23:table 23-L
  - intermittent claudication, 23:table 23-J
  - myocardial infarction, 23:table 23-D
  - noncardiovascular death, 23:table 23-O
  - nonsudden death from coronary heart disease, 23:table 23-G
  - other cardiovascular deaths, 23:table 23-N
  - sudden death from coronary heart disease, 23:table 23-F
  - uncomplicated angina pectoris, 23:table 23-E
- discriminant statistics in fatal vs. nonfatal coronary heart disease in men at 14-year followup, 23:table 23-C

SERUM CHOLESTEROL, Continued
- discriminant statistics in myocardial infarction vs. angina pectoris in men at 14-year followup, 23:table 23-B
- distribution of levels at exams 1-7, 9:table 9-A-5, 9:table 9-B-5
- distribution of levels by studies in pooling project, 31:figure 3
- incidence of disease according to, see guide 3 through guide 7
- level according to number of persons and number of specified events in studies of pooling project, 31:table 10
- mean level according to dietary intake:
  - animal fat, 24:table 13
  - animal fat and cholesterol, 24:table 18
  - caloric intake, 24:table 7
  - caloric intake per pound of body weight, 24:table 8
  - cholesterol, 24:table 17
  - fat, 24:table 12
  - percent fat from animal sources, 24:table 14
  - physical activity index and daily caloric intake, 24:table 10
  - ratio of complex to simple carbohydrates in food, 24:table 16
  - ratio of plant to animal fat, 24:table 15
- mean level by time of determination, exams 1-7, 23:figure 23-2
- mean level in men developing and not developing coronary heart disease, 23:figure 23-5
- mean of dietary characteristics by level of cholesterol 24:table 20
- mean value at exam 1 for all subjects, for subjects taking exam 10, and for subjects not taking exam 10, 29:table 3

SERUM CHOLESTEROL, Continued
  mean values and standard deviations of, in pooling project, 31:table 5
  mean values at exams 1-7, 4:table 4-9, see also guide no. 1
  mean values at exams 1-10, 29:table A-3
  mean values by disease status,
    men, 23:figure 23-7, 23:figure 23-13, 23:figure 23-19
    women, 23:figure 23-11, 23:figure 23-16, 23:figure 23-22
  mean values for subjects taking exam 10, 29:table B-3
  nomograms of CHD risk by level of cholesterol,
    40 years of age, 23:figure 23-24, 23:figure 23-30
    45 years of age, 23:figure 23-25, 23:figure 23-31
    50 years of age, 23:figure 23-26, 23:figure 23-32
    55 years of age, 23:figure 23-27, 23:figure 23-33
    60 years of age, 23:figure 23-28, 23:figure 23-34
    65 years of age, 23:figure 23-29, 23:figure 23-35
  probability of cardiovascular diseases by level of cholesterol,
    16-year followup, 27:tables 1B - 4B
    18-year followup, 28:tables 1 - 5
  regression coefficients for cardiovascular diseases on cholesterol, 27:tables 1 - 4
  regression on:
    animal fat, 24:table 19
    caloric intake, 24:table 11
    diet cholesterol, 24:table 19
    diet intake, 24:table 21
    Framingham relative weight, 24:table 11
    physical activity index, 24:table 11
    weight, 24:table 22
    weight change, 24:table 22
  standard errors at exams 1-7, 3:table 3-9
  variation, intraindividual, 29:table 3 appendix 2
  variation, standard deviation in pooling project, 31:table 5

SERUM PHOSPHOLIPIDS
  correlations with other characteristics, see guide 2
  determination of, 30:28
  distribution of levels at exams 1-7, 9:table 9-A-10, 9:table 9-B-10
  incidence of disease according to, see guide 3, guide 5, guide 7
  mean values at exams 1-7, 4:table 4-14, see also guide 1
  standard errors at exams 1-7, 3:table 3-14

SEX FACTORS
  death rates by sex for ages 35-59 for Framingham sample and town and for U. S. whites for years 1950-1952 and 1953-1956, 1:table 1-4
  deaths and age-adjusted death rates by sex for ages 30-59 for years 1950-1952, 1:table 1-3
  deaths and age-adjusted death rates by sex for ages 35-64 for years 1953-1957, 1:table 1-3
  differentials in risk factors related to incidence of coronary heart disease, atherothrombotic brain infarction and intermittent claudication, 16-year followup, 27:21-22
  drawn sample for ages 30-59, responses of, 1:table 1-1
  in actual and expected deaths of sample group not taking exam 1 for years 1953-1966, 1:table 1-7
  in actual and expected deaths of sample group taking exam 1 and volunteers for years 1953-1966, 1:table 1-6
  in actual and expected deaths of total drawn sample for years 1953-1966, 1:table 1-5
  in deaths and death rates for ages 45-74 by broad cause groups, 14-year followup, 1:table 1-9
  in deaths from specified causes according to response of drawn sample for years 1951-1952, 1:table 1-8

SEX FACTORS, Continued
  in mortality of sample nonrespondents for ages 45-69 for years 1953-1966, 1:figure 1-2
  in mortality of sample respondents for ages 45-69 for years 1953-1966, 1:figure 1-1
  men and women taking hypotensive drugs at exam 4-10, 29:before p. 28
  missing values for each of 23 characteristics studied according to sex for exams 1-10, 29:6
  number and percent of persons receiving exam 7 and exam 8 according to sex and age at exam 1, 2:table 4
  systolic blood pressure age trends by sex for exams 3-10, 29:27, 29:figure 1a

SMOKING, see also CIGARETTE SMOKING;
CIGARETTES SMOKED PER DAY
  habit according to number of persons and number of specified events in studies of pooling project, 31:table 11
  risk factor in studies of pooling project, mean values and standard deviations of, 31:table 5
  specified habits of populations in studies of pooling project, 31:table 4

STANDARDIZED COEFFICIENTS, 30:15

STATISTICAL DEFINITIONS
  age-adjusted rate, 30:11-12
  crude rate, actual, 30:10
  crude rate, smoothed, 30:10-11
  events, 30:8
  odds ratio, 27:3-4, 27:appendix A
  person years, 30:6-8

STATISTICAL DEFINITIONS, Continued
  rate, 30:8
  regression coefficient of the logistic function, 30:13-16
  smoothed rate, 30:8-10

STROKE: see CEREBROVASCULAR ACCIDENT

SUDDEN DEATH: see CORONARY HEART DISEASE DEATH

SURVIVAL, see also LIFE TABLES; MORTALITY
  following:
    brain infarction, 25:figure 7A
    cardiovascular events, 25:1-5, 32:table III-1 through table III-7
    cerebrovascular accident, 25:figure 6A, 25:figure 6B
    congestive heart failure, 25:figure 5A, 25:figure 5B, 25:figure 5C
    coronary attack, 25:figure 2A
    coronary heart disease, 25:figure 1A, 25:figure 1B, 25:figure 1C
    intermittent claudication, 25:figure 8A
    myocardial infarction, 25:figure 4A, 25:figure 4B, 25:figure 4C, 32:table III-8 through table III-13
    uncomplicated angina pectoris, 25:figure 3A

SYSTOLIC BLOOD PRESSURE: see BLOOD PRESSURE, SYSTOLIC

TECUMSEH STUDY: see POOLING PROJECT

URIC ACID, SERUM
  correlation with other characteristics, see guide 2
  determination of, 3:3-notes
  distribution of uric acid at exams 1-7, 9:table 9-A-11, 9:table 9-B-11
  incidence of disease according to, see guide 3, guide 5

URIC ACID, SERUM, Continued
  mean values at exams 1-7, 4:table 4-15, see also guide 1
  standard errors at exams 1-7, 3:table 3-15

URINE ALBUMIN
  correlation with other characteristics, see guide 2
  distribution of albumin at exams 1-7, 9:table 9-A-18, 9:table 9-B-18
  incidence of disease according to, see guide 3, guide 5, guide 7
  percent agreement between 2 exams, 29:table C-13
  percent at exam 1 by response to exam 10, 29:table 13
  percent at exams 1-7, 4:table 4-22, see also guide 1
  percent at exams 1-10, 29:table A-13, 29:table B-13
  testing for, 29:13-14, 30:37-38

URINE GLUCOSE
  age trends, exams 1-10, 29:figure 8
  correlation with other characteristics, see guide 2
  distribution of levels at exams 1-7, 9:table 9-A-19, 9:table 9-B-19
  incidence of disease according to, see guide 3, guide 5, guide 7
  percent agreement between 2 exams, 29:table C-14
  percent at exam 1 by response to exam 10, 29:table 14
  percent at exams 1-7, 4:table 4-23, see also guide 1
  percent at exams 1-10, 29:table A-14, 29:table B-14
  testing for, 29:14, 30:38

VARIATION IN MEASURED CHARACTERISTICS
  interexamination variation, section 29
  intraindividual variation, 29:appendix 2
  standard error at exams 1-7, 3:table 3-1 through table 3-17

VITAL CAPACITY
  age trends in, 29:35, 29:figure 6
  correlation between 2 exams, 29:table C-6
  correlation with other characteristics, see guide 2
  distribution of levels at exams 1-7, 9:table 9-A-12, 9:table 9-B-12
  incidence of disease according to, see guide 3, guide 5, guide 7
  mean value at exam 1 by response to exam 10, 29:table 6
  mean values at exams 1-7, 4:table 4-16, see also guide 1
  mean values at exams 1-10, 29:table A-6, 29:table B-6
  measurements of, 29:9-10
  standard errors at exams 1-7, 3:table 3-16
  variation, intraindividual, 29:table 6 appendix 2
  vital capacity-height index, determination of, 30:30

VOLUNTEERS
  actual and expected deaths by sex for years 1953-1966, 1:table 1-6
  examination dates for exams 1-7, 2:table 8
  number examined at each of first 8 examinations, 2:table 1
  number of persons according to examination status at exam 7 and at exam 8, 2:table 2
  number of persons according to examination status at exam 7 and at exam 8 in relation to number of biennial examinations received, 2:table 3
  number of persons not receiving exam 8 according to last biennial examination received, 2:table 5
  supplemental group, 1:1g-1 through 1g-3

WEIGHT: see BODY WEIGHT

Guide No. 1

Mean Values of Specified Characteristics at Exams 1 through 7

According to Whether a Person Entered as a Sample or Volunteer, When the Sample Person Entered the Study, and According to Followup, by Age at Exam 1 and Sex

CHARACTERISTICS / AGE GROUPS:	Males 29-39 at Exam 1	Males 40-49 at Exam 1	Males 50 & Over at Exam 1	Females 29-39 at Exam 1	Females 40-49 at Exam 1	Females 50 & Over at Exam 1
Alcohol consumption	3:3-1A	3:3-1B	3:3-1C	3:3-1D	3:3-1E	3:3-1F
Systolic BP at admission	3:3-2A	3:3-2B	3:3-2C	3:3-2D	3:3-2E	3:3-2F
Diastolic BP at admission	3:3-3A	3:3-3B	3:3-3C	3:3-3D	3:3-3E	3:3-3F
Systolic BP, 1st examiner	3:3-4A	3:3-4B	3:3-4C	3:3-4D	3:3-4E	3:3-4F
Diastolic BP, 1st examiner	3:3-5A	3:3-5B	3:3-5C	3:3-5D	3:3-5E	3:3-5F
Systolic BP, 2d examiner	3:3-6A	3:3-6B	3:3-6C	3:3-6D	3:3-6E	3:3-6F
Diastolic BP, 2d examiner	3:3-7A	3:3-7B	3:3-7C	3:3-7D	3:3-7E	3:3-7F
Blood sugar	3:3-8A	3:3-8B	3:3-8C	3:3-8D	3:3-8E	3:3-8F
Serum cholesterol	3:3-9A	3:3-9B	3:3-9C	3:3-9D	3:3-9E	3:3-9F
Cigarettes smoked/day	3:3-10A	3:3-10B	3:3-10C	3:3-10D	3:3-10E	3:3-10F
Framingham Relative Weight	3:3-11A	3:3-11B	3:3-11C	3:3-11D	3:3-11E	3:3-11F
Hematocrit	3:3-12A	3:3-12B	3:3-12C	3:3-12D	3:3-12E	3:3-12F
Hemoglobin	3:3-13A	3:3-13B	3:3-13C	3:3-13D	3:3-13E	3:3-13F
Phospholipids, serum	3:3-14A	3:3-14B	3:3-14C	3:3-14D	3:3-14E	3:3-14F
Uric acid, serum	3:3-15A	3:3-15B	3:3-15C	3:3-15D	3:3-15E	3:3-15F
Vital capacity	3:3-16A	3:3-16B	3:3-16C	3:3-16D	3:3-16E	3:3-16F
Body weight	3:3-17A	3:3-17B	3:3-17C	3:3-17D	3:3-17E	3:3-17F
ECG - definitely abnormal	3:3-18A	3:3-18B	3:3-18C	3:3-18D	3:3-18E	3:3-18F
ECG - left ventricular hypertrophy	3:3-19A	3:3-19B	3:3-19C	3:3-19D	3:3-19E	3:3-19F
ECG - non-specific T-wave abnormality	3:3-20A	3:3-20B	3:3-20C	3:3-20D	3:3-20E	3:3-20F
Smokers, now	3:3-21A	3:3-21B	3:3-21C	3:3-21D	3:3-21E	3:3-21F
Albumin, urine	3:3-22A	3:3-22B	3:3-22C	3:3-22D	3:3-22E	3:3-22F
Glucose, urine	3:3-23A	3:3-23B	3:3-23C	3:3-23D	3:3-23E	3:3-23F
X-ray - generalized cardiac enlargement	3:3-24A	3:3-24B	3:3-24C	3:3-24D	3:3-24E	3:3-24F
X-ray - heart enlargement	3:3-25A	3:3-25B	3:3-25C	3:3-25D	3:3-25E	3:3-25F
X-ray - left ventricular hypertrophy	3:3-26A	3:3-26B	3:3-26C	3:3-26D	3:3-26E	3:3-26F

Guide No. 2

Tables Analyzing Bivariate Correlations Among 26 Characteristics of the Framingham Cohort

At Exam 2 by Sex and Age

CHARACTERISTICS	Men	Women
Alcohol consumption	5:1A	5:1B
Systolic BP at admission	5:2A	5:2B
Diastolic BP at admission	5:3A	5:3B
Systolic BP, 1st examiner	5:4A	5:4B
Diastolic BP, 1st examiner	5:5A	5:5B
Systolic BP, 2d examiner	5:6A	5:6B
Diastolic BP, 2d examiner	5:7A	5:7B
Blood sugar	5:8A	5:8B
Serum cholesterol	5:9A	5:9B
Cigarettes smoked/day	5:10A	5:10B
Framingham Relative Weight	5:11A	5:11B
Hematocrit	NOT AVAILABLE	
Hemoglobin	5:13A	5:13B
Phospholipids, serum	5:14A	5:14B
Uric acid, serum	5:15A	5:15B
Vital capacity	5:16A	5:16B
Body weight	5:17A	5:17B
ECG - definitely abnormal	5:18A	5:18B
ECG - left ventricular hypertrophy	5:19A	5:19B
ECG - non-specific T-wave abnormality	5:20A	5:20B
Smokers, now	5:21A	5:21B
Albumin, urine	5:22A	5:22B
Glucose, urine	5:23A	5:23B
X-ray - generalized cardiac enlargement	5:24A	5:24B
X-ray - heart enlargement	5:25A	5:25B
X-ray - left ventricular hypertrophy	5:26A	5:26B

Guide No. 3

Tables Analyzing Incidence of Event by Sex, Age and Level of Characteristic at Exam

14-Year Followup

EVENTS: CHARACTERISTICS	Coronary Heart Disease (CHD)	Myocardial Infarction	Angina Pectoris Uncomplicated	Non-sudden Death from CHD	Cerebrovascular Accident	Brain Infarction
Alcohol consumed	10:10-A-1 10:10-B-1	11:11-A-1 11:11-B-1	12:12-A-1 12:12-B-1	14:14-A-1 14:14-B-1	15:15-A-1 15:15-B-1	16:16-A-1 16:16-B-1
Systolic Blood Pressure, 1st Examiner	10:10-A-2 10:10-B-2	11:11-A-2 11:11-B-2	12:12-A-2 12:12-B-2	14:14-A-2 14:14-B-2	15:15-A-2 15:15-B-2	16:16-A-2 16:16-B-2
Diastolic Blood Pressure, 1st Examiner	10:10-A-3 10:10-B-3	11:11-A-3 11:11-B-3	12:12-A-3 12:12-B-3	14:14-A-3 14:14-B-3	15:15-A-3 15:15-B-3	16:16-A-3 16:16-B-3
Blood sugar	10:10-A-4 10:10-B-4	11:11-A-4 11:11-B-4	12:12-A-4 12:12-B-4	14:14-A-4 14:14-B-4	15:15-A-4 15:15-B-4	16:16-A-4 16:16-B-4
Serum cholesterol	10:10-A-5 10:10-B-5	11:11-A-5 11:11-B-5	12:12-A-5 12:12-B-5	14:14-A-5 14:14-B-5	15:15-A-5 15:15-B-5	16:16-A-5 16:16-B-5
Cigarettes smoked/day	10:10-A-6 10:10-B-6	11:11-A-6 11:11-B-6	12:12-A-6 12:12-B-6	14:14-A-6 14:14-B-6	15:15-A-6 15:15-B-6	16:16-A-6 16:16-B-6
Framingham Relative Weight	10:10-A-7 10:10-B-7	11:11-A-7 11:11-B-7	12:12-A-7 12:12-B-7	14:14-A-7 14:14-B-7	15:15-A-7 15:15-B-7	16:16-A-7 16:16-B-7
Hematocrit	10:10-A-8 10:10-B-8	11:11-A-8 11:11-B-8	12:12-A-8 12:12-B-8	14:14-A-8 14:14-B-8	15:15-A-8 15:15-B-8	16:16-A-8 16:16-B-8
Hemoglobin	10:10-A-9 10:10-B-9	11:11-A-9 11:11-B-9	12:12-A-9 12:12-B-9	14:14-A-9 14:14-B-9	15:15-A-9 15:15-B-9	16:16-A-9 16:16-B-9
Phospholipids, serum	10:10-A-10 10:10-B-10	11:11-A-10 11:11-B-10	12:12-A-10 12:12-B-10	14:14-A-10 14:14-B-10	15:15-A-10 15:15-B-10	16:16-A-10 16:16-B-10
Uric Acid, serum	10:10-A-11 10:10-B-11	11:11-A-11 11:11-B-11	12:12-A-11 12:12-B-11	14:14-A-11 14:14-B-11	15:15-A-11 15:15-B-11	16:16-A-11 16:16-B-11
Vital capacity	10:10-A-12 10:10-B-12	11:11-A-12 11:11-B-12	12:12-A-12 12:12-B-12	14:14-A-12 14:14-B-12	15:15-A-12 15:15-B-12	16:16-A-12 16:16-B-12
Body Weight	10:10-A-13 10:10-B-13	11:11-A-13 11:11-B-13	12:12-A-13 12:12-B-13	14:14-A-13 14:14-B-13	15:15-A-13 15:15-B-13	16:16-A-13 16:16-B-13
ECG - definite abnormality	10:10-A-14 10:10-B-14	11:11-A-14 11:11-B-14	12:12-A-14 12:12-B-14	14:14-A-14 14:14-B-14	15:15-A-14 15:15-B-14	16:16-A-14 16:16-B-14
ECG - left ventricular hypertrophy	10:10-A-15 10:10-B-15	11:11-A-15 11:11-B-15	12:12-A-15 12:12-B-15	14:14-A-15 14:14-B-15	15:15-A-15 15:15-B-15	16:16-A-15 16:16-B-15
ECG - nonspecific T-wave abnormality	10:10-A-16 10:10-B-16	11:11-A-16 11:11-B-16	12:12-A-16 12:12-B-16	14:14-A-16 14:14-B-16	15:15-A-16 15:15-B-16	16:16-A-16 16:16-B-16
Smoking now	10:10-A-17 10:10-B-17	11:11-A-17 11:11-B-17	12:12-A-17 12:12-B-17	14:14-A-17 14:14-B-17	15:15-A-17 15:15-B-17	16:16-A-17 16:16-B-17
Urine Albumin	10:10-A-18 10:10-B-18	11:11-A-18 11:11-B-18	12:12-A-18 12:12-B-18	14:14-A-18 14:14-B-18	15:15-A-18 15:15-B-18	16:16-A-18 16:16-B-18
Urine Glucose	10:10-A-19 10:10-B-19	11:11-A-19 11:11-B-19	12:12-A-19 12:12-B-19	14:14-A-19 14:14-B-19	15:15-A-19 15:15-B-19	16:16-A-19 16:16-B-19
X-ray - generalized cardiac enlargement	10:10-A-20 10:10-B-20	11:11-A-20 11:11-B-20	12:12-A-20 12:12-B-20	14:14-A-20 14:14-B-20	15:15-A-20 15:15-B-20	16:16-A-20 16:16-B-20
X-ray - heart enlargement	10:10-A-21 10:10-B-21	11:11-A-21 11:11-B-21	12:12-A-21 12:12-B-21	14:14-A-21 14:14-B-21	15:15-A-21 15:15-B-21	16:16-A-21 16:16-B-21
X-ray - left ventricular hypertrophy	10:10-A-22 10:10-B-22	11:11-A-22 11:11-B-22	12:12-A-22 12:12-B-22	14:14-A-22 14:14-B-22	15:15-A-22 15:15-B-22	16:16-A-22 16:16-B-22

A Tables = 10-year age groups
B Tables = 5-year age groups

Guide No. 3, Continued

Tables Analyzing Incidence of Event by Sex, Age and Level of Characteristic at Exam

14-Year Followup

EVENTS: CHARACTERISTICS	Intermittent Claudication	Congestive Heart Failure	Death from All Causes	Death from CHD	Death from Cardiovasc. Disease Other than CHD	Death from Causes other than Cardio-vascular Disease
Alcohol consumed	17:17-A-1 17:17-B-1	18:18-A-1 18:18-B-1	19:19-A-1 19:19-B-1	20:20-A-1 20:20-B-1	21:21-A-1 21:21-B-1	22:22-A-1 22:22-B-1
Systolic Blood Pressure, 1st Examiner	17:17-A-2 17:17-B-2	18:18-A-2 18:18-B-2	19:19-A-2 19:19-B-2	20:20-A-2 20:20-B-2	21:21-A-2 21:21-B-2	22:22-A-2 22:22-B-2
Diastolic Blood Pressure, 1st Examiner	17:17-A-3 17:17-B-3	18:18-A-3 18:18-B-3	19:19-A-3 19:19-B-3	20:20-A-3 20:20-B-3	21:21-A-3 21:21-B-3	22:22-A-3 22:22-B-3
Blood sugar	17:17-A-4 17:17-B-4	18:18-A-4 18:18-B-4	19:19-A-4 19:19-B-4	20:20-A-4 20:20-B-4	21:21-A-4 21:21-B-4	22:22-A-4 22:22-B-4
Serum cholesterol	17:17-A-5 17:17-B-5	18:18-A-5 18:18-B-5	19:19-A-5 19:19-B-5	20:20-A-5 20:20-B-5	21:21-A-5 21:21-B-5	22:22-A-5 22:22-B-5
Cigarettes smoked/day	17:17-A-6 17:17-B-6	18:18-A-6 18:18-B-6	19:19-A-6 19:19-B-6	20:20-A-6 20:20-B-6	21:21-A-6 21:21-B-6	22:22-A-6 22:22-B-6
Framingham Relative Weight	17:17-A-7 17:17-B-7	18:18-A-7 18:18-B-7	19:19-A-7 19:19-B-7	20:20-A-7 20:20-B-7	21:21-A-7 21:21-B-7	22:22-A-7 22:22-B-7
Hematocrit	17:17-A-8 17:17-B-8	18:18-A-8 18:18-B-8	19:19-A-8 19:19-B-8	20:20-A-8 20:20-B-8	21:21-A-8 21:21-B-8	22:22-A-8 22:22-B-8
Hemoglobin	17:17-A-9 17:17-B-9	18:18-A-9 18:18-B-9	19:19-A-9 19:19-B-9	20:20-A-9 20:20-B-9	21:21-A-9 21:21-B-9	22:22-A-9 22:22-B-9
Phospholipids, serum	17:17-A-10 17:17-B-10	18:18-A-10 18:18-B-10	19:19-A-10 19:19-B-10	20:20-A-10 20:20-B-10	21:21-A-10 21:21-B-10	22:22-A-10 22:22-B-10
Uric Acid, serum	17:17-A-11 17:17-B-11	18:18-A-11 18:18-B-11	19:19-A-11 19:19-B-11	20:20-A-11 20:20-B-11	21:21-A-11 21:21-B-11	22:22-A-11 22:22-B-11
Vital capacity	17:17-A-12 17:17-B-12	18:18-A-12 18:18-B-12	19:19-A-12 19:19-B-12	20:20-A-12 20:20-B-12	21:21-A-12 21:21-B-12	22:22-A-12 22:22-B-12
Body Weight	17:17-A-13 17:17-B-13	18:18-A-13 18:18-B-13	19:19-A-13 19:19-B-13	20:20-A-13 20:20-B-13	21:21-A-13 21:21-B-13	22:22-A-13 22:22-B-13
ECG - definite abnormality	17:17-A-14 17:17-B-14	18:18-A-14 18:18-B-14	19:19-A-14 19:19-B-14	20:20-A-14 20:20-B-14	21:21-A-14 21:21-B-14	22:22-A-14 22:22-B-14
ECG - left ventricular hypertrophy	17:17-A-15 17:17-B-15	18:18-A-15 18:18-B-15	19:19-A-15 19:19-B-15	20:20-A-15 20:20-B-15	21:21-A-15 21:21-B-15	22:22-A-15 22:22-B-15
ECG - nonspecific T-wave abnormality	17:17-A-16 17:17-B-16	18:18-A-16 18:18-B-16	19:19-A-16 19:19-B-16	20:20-A-16 20:20-B-16	21:21-A-16 21:21-B-16	22:22-A-16 22:22-B-16
Smoking now	17:17-A-17 17:17-B-17	18:18-A-17 18:18-B-17	19:19-A-17 19:19-B-17	20:20-A-17 20:20-B-17	21:21-A-17 21:21-B-17	22:22-A-17 22:22-B-17
Urine Albumin	17:17-A-18 17:17-B-18	18:18-A-18 18:18-B-18	19:19-A-18 19:19-B-18	20:20-A-18 20:20-B-18	21:21-A-18 21:21-B-18	22:22-A-18 22:22-B-18
Urine Glucose	17:17-A-19 17:17-B-19	18:18-A-19 18:18-B-19	19:19-A-19 19:19-B-19	20:20-A-19 20:20-B-19	21:21-A-19 21:21-B-19	22:22-A-19 22:22-B-19
X-ray - generalized cardiac enlargement	17:17-A-20 17:17-B-20	18:18-A-20 18:18-B-20	19:19-A-20 19:19-B-20	20:20-A-20 20:20-B-20	21:21-A-20 21:21-B-20	22:22-A-20 22:22-B-20
X-ray - heart enlargement	17:17-A-21 17:17-B-21	18:18-A-21 18:18-B-21	19:19-A-21 19:19-B-21	20:20-A-21 20:20-B-21	21:21-A-21 21:21-B-21	22:22-A-21 22:22-B-21
X-ray - left ventricular hypertrophy	17:17-A-22 17:17-B-22	18:18-A-22 18:18-B-22	19:19-A-22 19:19-B-22	20:20-A-22 20:20-B-22	21:21-A-22 21:21-B-22	22:22-A-22 22:22-B-22

A Tables = 10-year age groups
B Tables = 5-year age groups

Guide No. 4

Tables Analyzing Discrimination of Various Cardiovascular Events and Deaths

on the Basis of Three Characteristics: Framingham Relative Weight, Systolic Blood Pressure and Serum Cholesterol
in Various Age-Sex Groups, at Exams 2, 4 and 6 Pooled

EVENTS:	Coronary Heart Disease (CHD)	Myocardial Infarction	Angina Pectoris Uncomplicated	Sudden Death from CHD	Non-Sudden Death from CHD	Cerebrovascular Accident	Brain Infarction
AGE GROUPS							
38 - 41	23:23-A-1.1	23:23-A-2.1					
42 - 45	23:23-A-1.2 23:23-B-1.2	23:23-A-2.2	23:23-A-3.2 23:23-B-3.2				
46 - 49	23:23-A-1.3 23:23-B-1.3	23:23-A-2.3	23:23-A-3.3 23:23-B-3.3			23:23-A-6.3 23:23-B-6.3	
50 - 53	23:23-A-1.4 23:23-B-1.4	23:23-A-2.4	23:23-A-3.4 23:23-B-3.4	23:23-A-4.4	23:23-A-5.4	23:23-A-6.4 23:23-B-6.4	23:23-A-7.4 23:23-B-7.4
54 - 57	23:23-A-1.5 23:23-B-1.5	23:23-A-2.5 23:23-B-2.5	23:23-A-3.5 23:23-B-3.5	23:23-A-4.5	23:23-A-5.5	23:23-A-6.5 23:23-B-6.5	23:23-A-7.5 23:23-B-7.5
58 - 61	23:23-A-1.6 23:23-B-1.6	23:23-A-2.6 23:23-B-2.6	23:23-A-3.6 23:23-B-3.6	23:23-A-4.6	23:23-A-5.6	23:23-A-6.6 23:23-B-6.6	23:23-A-7.6 23:23-B-7.6
62 - 65	23:23-A-1.7 23:23-B-1.7	23:23-A-2.7 23:23-B-2.7	23:23-A-3.7 23:23-B-3.7		23:23-A-5.7	23:23-A-6.7 23:23-B-6.7	23:23-A-7.7 23:23-B-7.7
66 - 69	23:23-A-1.8 23:23-B-1.8	23:23-A-2.8	23:23-B-3.8			23:23-A-6.8 23:23-B-6.8	23:23-B-7.8

A Tables = Men
B Tables = Women

Guide No. 4, Continued

Tables Analyzing Discrimination of Various Cardiovascular Events and Deaths

on the Basis of Three Characteristics: Framingham Relative Weight, Systolic Blood Pressure and Serum Cholesterol in Various Age-Sex Groups, at Exams 2, 4 and 6 Pooled

EVENTS:	Intermittent Claudication	Congestive Heart Failure	Death from All Causes	Death from CHD	Death from Cardiovasc. Disease Other than CHD	Death from Causes other than Cardio-vascular Disease
AGE GROUPS						
38 - 41			23:23-A-10.1 23:23-B-10.1			23:23-B-13.1
42 - 45	23:23-A-8.2		23:23-A-10.2 23:23-B-10.2	23:23-A-11.2		23:23-B-13.2
46 - 49	23:23-A-8.3	23:23-A-9.3	23:23-A-10.3 23:23-B-10.3	23:23-A-11.3		23:23-A-13.3 23:23-B-13.3
50 - 53		23:23-A-9.4	23:23-A-10.4 23:23-B-10.4	23:23-A-11.4		23:23-A-13.4 23:23-B-13.4
54 - 57	23:23-A-8.5 23:23-B-8.5	23:23-A-9.5 23:23-B-9.5	23:23-A-10.5 23:23-B-10.5	23:23-A-11.5	23:23-A-12.5 23:23-B-12.5	23:23-A-13.5 23:23-B-13.5
58 - 61	23:23-A-8.6 23:23-B-8.6	23:23-A-9.6 23:23-B-9.6	23:23-A-10.6 23:23-B-10.6	23:23-A-11.6 23:23-B-11.6	23:23-A-12.6 23:23-B-12.6	23:23-A-13.6 23:23-B-13.6
62 - 65	23:23-A-8.7 23:23-B-8.7	23:23-A-9.7 23:23-B-9.7	23:23-A-10.7 23:23-B-10.7	23:23-A-11.7 23:23-B-11.7	23:23-A-12.7 23:23-B-12.7	23:23-A-13.7 23:23-B-13.7
66 - 69	23:23-A-8.8 23:23-B-8.8	23:23-A-9.8	23:23-A-10.8 23:23-B-10.8	23:23-A-11.8 23:23-B-11.8		23:23-A-13.8 23:23-B-13.8

A Tables = Men
B Tables = Women

Guide No. 5

Tables Analyzing Characteristics Related to the Incidence of Cardiovascular Disease and Death

16-Year Followup

EVENTS: CHARACTERISTICS	Coronary Heart Disease (CHD)	CHD Other Than Angina Pectoris	Myocardial Infarction	Angina Pectoris Uncomplicated	Sudden Death from CHD	Sudden and Unexpected Death from CHD	Non-Sudden Death from CHD
Systolic BP, 1st examiner	26:1-1-A 26:1-1-B	26:2-1-A 26:2-1-B	26:3-1-A 26:3-1-B	26:4-1-A 26:4-1-B	26:5-1-A 26:5-1-B	26:6-1-A 26:6-1-B	26:7-1-A 26:7-1-B
Diastolic BP, 1st examiner	26:1-2-A 26:1-2-B	26:2-2-A 26:2-2-B	26:3-2-A 26:3-2-B	26:4-2-A 26:4-2-B	26:5-2-A 26:5-2-B	26:6-2-A 26:6-2-B	26:7-2-A 26:7-2-B
Serum cholesterol	26:1-3-A 26:1-3-B	26:2-3-A 26:2-3-B	26:3-3-A 26:3-3-B	26:4-3-A 26:4-3-B	26:5-3-A 26:5-3-B	26:6-3-A 26:6-3-B	26:7-3-A 26:7-3-B
Hemoglobin	26:1-4-A 26:1-4-B	26:2-4-A 26:2-4-B	26:3-4-A 26:3-4-B	26:4-4-A 26:4-4-B	26:5-4-A 26:5-4-B	26:6-4-A 26:6-4-B	26:7-4-A 26:7-4-B
Phospholipids, serum	26:1-5-A 26:1-5-B	26:2-5-A 26:2-5-B	26:3-5-A 26:3-5-B	26:4-5-A 26:4-5-B	26:5-5-A 26:5-5-B	26:6-5-A 26:6-5-B	26:7-5-A 26:7-5-B
Blood sugar	26:1-6-A 26:1-6-B	26:2-6-A 26:2-6-B	26:3-6-A 26:3-6-B	26:4-6-A 26:4-6-B	26:5-6-A 26:5-6-B	26:6-6-A 26:6-6-B	26:7-6-A 26:7-6-B
Uric acid, serum	26:1-7-A 26:1-7-B	26:2-7-A 26:2-7-B	26:3-7-A 26:3-7-B	26:4-7-A 26:4-7-B	26:5-7-A 26:5-7-B	26:6-7-A 26:6-7-B	26:7-7-A 26:7-7-B
Framingham Relative Weight	26:1-8-A 26:1-8-B	26:2-8-A 26:2-8-B	26:3-8-A 26:3-8-B	26:4-8-A 26:4-8-B	26:5-8-A 26:5-8-B	26:6-8-A 26:6-8-B	26:7-8-A 26:7-8-B
Vital capacity	26:1-9-A 26:1-9-B	26:2-9-A 26:2-9-B	26:3-9-A 26:3-9-B	26:4-9-A 26:4-9-B	26:5-9-A 26:5-9-B	26:6-9-A 26:6-9-B	26:7-9-A 26:7-9-B
Alcohol consumed	26:1-10-A 26:1-10-B	26:2-10-A 26:2-10-B	26:3-10-A 26:3-10-B	26:4-10-A 26:4-10-B	26:5-10-A 26:5-10-B	26:6-10-A 26:6-10-B	26:7-10-A 26:7-10-B
Cigarettes smoked/day	26:1-11-A 26:1-11-B	26:2-11-A 26:2-11-B	26:3-11-A 26:3-11-B	26:4-11-A 26:4-11-B	26:5-11-A 26:5-11-B	26:6-11-A 26:6-11-B	26:7-11-A 26:7-11-B
Urine albumin	26:1-12-A 26:1-12-B	26:2-12-A 26:2-12-B	26:3-12-A 26:3-12-B	26:4-12-A 26:4-12-B	26:5-12-A 26:5-12-B	26:6-12-A 26:6-12-B	26:7-12-A 26:7-12-B
Urine sugar	26:1-13-A 26:1-13-B	26:2-13-A 26:2-13-B	26:3-13-A 26:3-13-B	26:4-13-A 26:4-13-B	26:5-13-A 26:5-13-B	26:6-13-A 26:6-13-B	26:7-13-A 26:7-13-B
X-ray - heart enlargement	26:1-14-A 26:1-14-B	26:2-14-A 26:2-14-B	26:3-14-A 26:3-14-B	26:4-14-A 26:4-14-B	26:5-14-A 26:5-14-B	26:6-14-A 26:6-14-B	26:7-14-A 26:7-14-B
ECG - left ventricular hypertrophy	26:1-15-A 26:1-15-B	26:2-15-A 26:2-15-B	26:3-15-A 26:3-15-B	26:4-15-A 26:4-15-B	26:5-15-A 26:5-15-B	26:6-15-A 26:6-15-B	26:7-15-A 26:7-15-B
ECG - nonspecific T-wave abnorm.	26:1-16-A 26:1-16-B	26:2-16-A 26:2-16-B	26:3-16-A 26:3-16-B	26:4-16-A 26:4-16-B	26:5-16-A 26:5-16-B	26:6-16-A 26:6-16-B	26:7-16-A 26:7-16-B
Diabetes mellitus	26:1-17-A 26:1-17-B	26:2-17-A 26:2-17-B	26:3-17-A 26:3-17-B	26:4-17-A 26:4-17-B	26:5-17-A 26:5-17-B	26:6-17-A 26:6-17-B	26:7-17-A 26:7-17-B
Hypertension	26:1-18-A 26:1-18-B	26:2-18-A 26:2-18-B	26:3-18-A 26:3-18-B	26:4-18-A 26:4-18-B	26:5-18-A 26:5-18-B	26:6-18-A 26:6-18-B	26:7-18-A 26:7-18-B
Glucose intolerance	26:1-19-A 26:1-19-B	26:2-19-A 26:2-19-B	26:3-19-A 26:3-19-B	26:4-19-A 26:4-19-B	26:5-19-A 26:5-19-B	26:6-19-A 26:6-19-B	26:7-19-A 26:7-19-B

A Tables = Incidence of event after specified exam, by sex, age and level of characteristic at exam.

B Tables = Average annual incidence rate at exam, by sex, age and level of characteristic at exam.

Guide No. 5, Continued

Tables Analyzing Characteristics Related to the Incidence of Cardiovascular Disease and Death

16-Year Followup

EVENTS: CHARACTERISTICS	Cerebro-vascular Accident	Athero-thrombotic Brain Infarction	Intermittent Claudication	Congestive Heart Failure	Death from All Causes	Death from CHD	Death from Cardiovasc. Disease other than CHD
Systolic BP, 1st examiner	26:8-1-A 26:8-1-B	26:9-1-A 26:9-1-B	26:10-1-A 26:10-1-B	26:11-1-A 26:11-1-B	26:12-1-A 26:12-1-B	26:13-1-A 26:13-1-B	26:14-1-A 26:14-1-B
Diastolic BP, 1st examiner	26:8-2-A 26:8-2-B	26:9-2-A 26:9-2-B	26:10-2-A 26:10-2-B	26:11-2-A 26:11-2-B	26:12-2-A 26:12-2-B	26:13-2-A 26:13-2-B	26:14-2-A 26:14-2-B
Serum cholesterol	26:8-3-A 26:8-3-B	26:9-3-A 26:9-3-B	26:10-3-A 26:10-3-B	26:11-3-A 26:11-3-B	26:12-3-A 26:12-3-B	26:13-3-A 26:13-3-B	26:14-3-A 26:14-3-B
Hemoglobin	26:8-4-A 26:8-4-B	26:9-4-A 26:9-4-B	26:10-4-A 26:10-4-B	26:11-4-A 26:11-4-B	26:12-4-A 26:12-4-B	26:13-4-A 26:13-4-B	26:14-4-A 26:14-4-B
Phospholipids, serum	26:8-5-A 26:8-5-B	26:9-5-A 26:9-5-B	26:10-5-A 26:10-5-B	26:11-5-A 26:11-5-B	26:12-5-A 26:12-5-B	26:13-5-A 26:13-5-B	26:14-5-A 26:14-5-B
Blood sugar	26:8-6-A 26:8-6-B	26:9-6-A 26:9-6-B	26:10-6-A 26:10-6-B	26:11-6-A 26:11-6-B	26:12-6-A 26:12-6-B	26:13-6-A 26:13-6-B	26:14-6-A 26:14-6-B
Uric acid, serum	26:8-7-A 26:8-7-B	26:9-7-A 26:9-7-B	26:10-7-A 26:10-7-B	26:11-7-A 26:11-7-B	26:12-7-A 26:12-7-B	26:13-7-A 26:13-7-B	26:14-7-A 26:14-7-B
Framingham Relative Weight	26:8-8-A 26:8-8-B	26:9-8-A 26:9-8-B	26:10-8-A 26:10-8-B	26:11-8-A 26:11-8-B	26:12-8-A 26:12-8-B	26:13-8-A 26:13-8-B	26:14-8-A 26:14-8-B
Vital capacity	26:8-9-A 26:8-9-B	26:9-9-A 26:9-9-B	26:10-9-A 26:10-9-B	26:11-9-A 26:11-9-B	26:12-9-A 26:12-9-B	26:13-9-A 26:13-9-B	26:14-9-A 26:14-9-B
Alcohol consumed	26:8-10-A 26:8-10-B	26:9-10-A 26:9-10-B	26:10-10-A 26:10-10-B	26:11-10-A 26:11-10-B	26:12-10-A 26:12-10-B	26:13-10-A 26:13-10-B	26:14-10-A 26:14-10-B
Cigarettes smoked/day	26:8-11-A 26:8-11-B	26:9-11-A 26:9-11-B	26:10-11-A 26:10-11-B	26:11-11-A 26:11-11-B	26:12-11-A 26:12-11-B	26:13-11-A 26:13-11-B	26:14-11-A 26:14-11-B
Urine albumin	26:8-12-A 26:8-12-B	26:9-12-A 26:9-12-B	26:10-12-A 26:10-12-B	26:11-12-A 26:11-12-B	26:12-12-A 26:12-12-B	26:13-12-A 26:13-12-B	26:14-12-A 26:14-12-B
Urine sugar	26:8-13-A 26:8-13-B	26:9-13-A 26:9-13-B	26:10-13-A 26:10-13-B	26:11-13-A 26:11-13-B	26:12-13-A 26:12-13-B	26:13-13-A 26:13-13-B	26:14-13-A 26:14-13-B
X-ray - heart enlargement	26:8-14-A 26:8-14-B	26:9-14-A 26:9-14-B	26:10-14-A 26:10-14-B	26:11-14-A 26:11-14-B	26:12-14-A 26:12-14-B	26:13-14-A 26:13-14-B	26:14-14-A 26:14-14-B
ECG - left ventricular hypertrophy	26:8-15-A 26:8-15-B	26:9-15-A 26:9-15-B	26:10-15-A 26:10-15-B	26:11-15-A 26:11-15-B	26:12-15-A 26:12-15-B	26:13-15-A 26:13-15-B	26:14-15-A 26:14-15-B
ECG - nonspecific T-wave abnorm.	26:8-16-A 26:8-16-B	26:9-16-A 26:9-16-B	26:10-16-A 26:10-16-B	26:11-16-A 26:11-16-B	26:12-16-A 26:12-16-B	26:13-16-A 26:13-16-B	26:14-16-A 26:14-16-B
Diabetes mellitus	26:8-17-A 26:8-17-B	26:9-17-A 26:9-17-B	26:10-17-A 26:10-17-B	26:11-17-A 26:11-17-B	26:12-17-A 26:12-17-B	26:13-17-A 26:13-17-B	26:14-17-A 26:14-17-B
Hypertension	26:8-18-A 26:8-18-B	26:9-18-A 26:9-18-B	26:10-18-A 26:10-18-B	26:11-18-A 26:11-18-B	26:12-18-A 26:12-18-B	26:13-18-A 26:13-18-B	26:14-18-A 26:14-18-B
Glucose intolerance	26:8-19-A 26:8-19-B	26:9-19-A 26:9-19-B	26:10-19-A 26:10-19-B	26:11-19-A 26:11-19-B	26:12-19-A 26:12-19-B	26:13-19-A 26:13-19-B	26:14-19-A 26:14-19-B

A Tables = Incidence of event after specified exam, by sex, age, and level of characteristic at exam.

B Tables = Average annual incidence rate at exam, by sex, age, and level of characteristic at exam.

Guide No. 6

Tables Analyzing Relative Average Odds of Specified Event by Sex, Age and Level of Characteristic at Exam

16-Year Followup

EVENTS: CHARACTERISTICS Other 4 Characteristics Serve as Control Variables in Each Case	Coronary Heart Disease (CHD)	CHD Other Than Angina Pectoris	Angina Pectoris, Uncomplicated	Athero-Thrombotic Brain Infarction	Intermittent Claudication
Systolic BP, 1st examiner	27:1A-1	27:2A-1	27:3A-1	27:4A-1	27:5A-1
	27:1A-2	27:2A-2	27:3A-2	27:4A-2	27:5A-2
Serum cholesterol	27:1A-1	27:2A-1	27:3A-1	27:4A-1	27:5A-1
	27:1A-2	27:2A-2	27:3A-2	27:4A-2	27:5A-2
Cigarettes smoked/day	27:1A-1	27:2A-1	27:3A-1	27:4A-1	27:5A-1
	27:1A-2	27:2A-2	27:3A-2	27:4A-2	27:5A-2
ECG - left ventricular hypertrophy	27:1A-1	27:2A-1	27:3A-1	27:4A-1	27:5A-1
	27:1A-2	27:2A-2	27:3A-2	27:4A-2	27:5A-2
Glucose intolerance	27:1A-1	27:2A-1	27:3A-1	27:4A-1	27:5A-1
	27:1A-2	27:2A-2	27:3A-2	27:4A-2	27:5A-2

A-1 Tables = Men
A-2 Tables = Women

Guide No. 7

Tables Analyzing Average Annual Incidence Rate for Event per 10,000 Persons at Risk at Exam

by Sex, Age and Level of Characteristic at Exam

18-Year Followup

EVENTS: CHARACTERISTICS	Coronary Heart Disease (CHD)	CHD Other than Angina Pectoris	Myocardial Infarction	Coronary Insufficiency	Angina Pectoris Uncomplicated	Death from CHD	Sudden Death from CHD
Systolic BP, 1st examiner	30:1-1	30:2-1	30:3-1	30:4-1	30:5-1	30:6-1	30:7-1
Diastolic BP, 1st examiner	30:1-2	30:2-2	30:3-2	30:4-2	30:5-2	30:6-2	30:7-2
Serum cholesterol	30:1-3	30:2-3	30:3-3	30:4-3	30:5-3	30:6-3	30:7-3
Phospholipids, serum	30:1-4	30:2-4	30:3-4	30:4-4	30:5-4	30:6-4	30:7-4
Blood glucose	30:1-5	30:2-5	30:3-5	30:4-5	30:5-5	30:6-5	30:7-5
Metropolitan relative weight	30:1-6	30:2-6	30:3-6	30:4-6	30:5-6	30:6-6	30:7-6
Vital capacity-height index	30:1-7	30:2-7	30:3-7	30:4-7	30:5-7	30:6-7	30:7-7
Pulse rate	30:1-8	30:2-8	30:3-8	30:4-8	30:5-8	30:6-8	30:7-8
Cigarettes smoked/day	30:1-9	30:2-9	30:3-9	30:4-9	30:5-9	30:6-9	30:7-9
Hypertension	30:1-10	30:2-10	30:3-10	30:4-10	30:5-10	30:6-10	30:7-10
Heart enlargement by x-ray	30:1-11	30:2-11	30:3-11	30:4-11	30:5-11	30:6-11	30:7-11
Left ventricular hypertrophy by electrocardiogram	30:1-12	30:2-12	30:3-12	30:4-12	30:5-12	30:6-12	30:7-12
Intraventricular conduction defect	30:1-13	30:2-13	30:3-13	30:4-13	30:5-13	30:6-13	30:7-13
Nonspecific T-wave or ST-segment abnormality by electrocardiogram	30:1-14	30:2-14	30:3-14	30:4-14	30:5-14	30:6-14	30:7-14
Albumin in urine	30:1-15	30:2-15	30:3-15	30:4-15	30:5-15	30:6-15	30:7-15
Glucose in urine	30:1-16	30:2-16	30:3-16	30:4-16	30:5-16	30:6-16	30:7-16
Diabetes mellitus	30:1-17	30:2-17	30:3-17	30:4-17	30:5-17	30:6-17	30:7-17
Glucose intolerance	30:1-18	30:2-18	30:3-18	30:4-18	30:5-18	30:6-18	30:7-18

Guide No. 7, Continued

Tables Analyzing Average Annual Incidence Rate for Event per 10,000 Persons at Risk at Exam by Sex, Age and Level of Characteristic at Exam

18-Year Followup

EVENTS: **CHARACTERISTICS**	Cerebro-vascular Accident	Athero-thrombotic Brain Infarction	Intermittent Claudication	Congestive Heart Failure	Death from All Causes	Death from Cardiovas-cular Disease	Cardiovas-cular Disease
Systolic BP, 1st examiner	30:8-1	30:9-1	30:10-1	30:11-1	30:12-1	30:13-1	30:14-1
Diastolic BP, 1st examiner	30:8-2	30:9-2	30:10-2	30:11-2	30:12-2	30:13-2	30:14-2
Serum cholesterol	30:8-3	30:9-3	30:10-3	30:11-3	30:12-3	30:13-3	30:14-3
Phospholipids, serum	30:8-4	30:9-4	30:10-4	30:11-4	30:12-4	30:13-4	30:14-4
Blood glucose	30:8-5	30:9-5	30:10-5	30:11-5	30:12-5	30:13-5	30:14-5
Metropolitan relative weight	30:8-6	30:9-6	30:10-6	30:11-6	30:12-6	30:13-6	30:14-6
Vital capacity-height index	30:8-7	30:9-7	30:10-7	30:11-7	30:12-7	30:13-7	30:14-7
Pulse rate	30:8-8	30:9-8	30:10-8	30:11-8	30:12-8	30:13-8	30:14-8
Cigarettes smoked/day	30:8-9	30:9-9	30:10-9	30:11-9	30:12-9	30:13-9	30:14-9
Hypertension	30:8-10	30:9-10	30:10-10	30:11-10	30:12-10	30:13-10	30:14-10
Heart enlargement by x-ray	30:8-11	30:9-11	30:10-11	30:11-11	30:12-11	30:13-11	30:14-11
Left ventricular hypertrophy by electrocardiogram	30:8-12	30:9-12	30:10-12	30:11-12	30:12-12	30:13-12	30:14-12
Intraventricular conduction defect	30:8-13	30:9-13	30:10-13	30:11-13	30:12-13	30:13-13	30:14-13
Nonspecific T-wave or ST-segment abnormality by electrocardiogram	30:8-14	30:9-14	30:10-14	30:11-14	30:12-14	30:13-14	30:14-14
Albumin in urine	30:8-15	30:9-15	30:10-15	30:11-15	30:12-15	30:13-15	30:14-15
Glucose in urine	30:8-16	30:9-16	30:10-16	30:11-16	30:12-16	30:13-16	30:14-16
Diabetes mellitus	30:8-17	30:9-17	30:10-17	30:11-17	30:12-17	30:13-17	30:14-17
Glucose intolerance	30:8-18	30:9-18	30:10-18	30:11-18	30:12-18	30:13-18	30:14-18

☆ U.S. GOVERNMENT PRINTING OFFICE : 1979 O—281-217 (3130)

Library
National Institutes of Health
Bethesda, Maryland 20014

DISCRIMINATION PROHIBITED: Under provisions of
applicable public laws enacted by Congress since 1964,
no person in the United States shall, on the ground of
race, col origin, sex, or handicap, be
excluded ed the benefits
of, or be nder any pro-
gram or ancial assistance.
In addit hibits discrimina-
tion on s and subcon-
tractors contracts.
Therefo and Blood Institute
must be hese laws and
executi

DATE DUE

GAYLORD

PRINTED IN U.S.A.

LIBRARY
NIH
Amazing Research.
Amazing Help.
http://nihlibrary.nih.gov

10 Center Drive
Bethesda, MD 20892-1150
301-496-1080

NIH LIBRARY
4 0121 2305

NIH LIBRARY
3 1496 00191 7205

~~DEC 20 1985~~
~~DEC 20 1988~~
~~JUL 11~~

NIH PUBLICATION NO. 79-1671
December, 1978